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Abstract 
Acquisition of Estrogen Independence Induces Distinct Mechanisms Supporting 
Cell Proliferation and Survival 
Rochelle Elizabeth Nasto 
 
 
 
De novo and acquired resistance to anti-estrogen therapy and aromatase 
inhibitors remains a challenge in the treatment of estrogen-receptor positive 
breast cancer. We employed a systems biology approach to identify survival 
determinants of estrogen independent breast cancer cells with varying 
sensitivities to hormonal therapeutics.  An estrogen receptor-centered network 
was developed using bioinformatics databases to probe, with a network-targeted 
631-element siRNA library, for essential genes involved in the proliferation and 
survival of estrogen independent breast cancer cells.  We identified a unique 
subset of 25 genes that are essential for the proliferation of estrogen 
independent breast cancer cells, 15 of which also promote apoptosis.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
1 
Chapter 1: Introduction and Background 
 
Great progress has been made in understanding and treating breast cancer 
since the report of the first clinical trial with hormonal therapeutic, tamoxifen, in 
1971 [3], which has led to a reduction in incidence and death over the past 
several decades.  However, breast cancer is the second leading cause of cancer 
death in woman.  The American Cancer Society estimates almost 40,000 deaths 
from breast cancer and over 230,00 new diagnoses of invasive breast cancer in 
2013.  Approximately two thirds of woman diagnosed with breast cancer are 
estrogen receptor (ER) positive [4].   
 
Women with ER positive breast cancer typically receive adjuvant hormone 
therapy, a treatment given after surgery.  The type of treatment depends on 
whether the woman is premenopausal or postmenopausal.  The first line 
treatment for premenopausal women is tamoxifen and for postmenopausal 
women is aromatase inhibitors.  Fulvestrant is another targeted therapy used as 
a second line treatment once drug resistance occurs. Tamoxifen functions to 
block ligand bound ER activity in breast tissue.  Fulvestrant also targets the ER, 
however, it functions to tag the ER for degradation[5].  Therapies targeting the 
estrogen receptor are referred to as anti-estrogens (AE).  Aromatase inhibitors 
(AI) act differently by blocking the synthesis of estrogen in adipose tissue.  These 
treatments are successful in extending survival in woman however, de novo and 
acquired resistance occur in about half of the cases.  Chemotherapy is the next 
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course of treatment and many women will succumb to their disease.  
Understanding drug resistance and finding new treatments is important for 
improving survival in women who become resistant to the current targeted 
hormonal therapies.   
 
De novo and acquired drug resistance to AEs and AIs pose significant 
challenges to the effective treatment of ER positive breast cancers.  Numerous 
resistance mechanisms have been identified, including the loss of ER 
expression, epigenetic changes, altered expression or activation of cellular 
signaling proteins that generally promote survival (e.g. epithelial growth factor 
receptor (EGFR), insulin-like growth factor receptor (IGFR), PI3K/AKT, mTOR 
signaling and NFκB), and altered expression of specific miRNAs [6-8]. In light of 
this research, AE and AI resistance remains poorly understood.  For hormone 
therapy-resistant breast cancer, chemotherapy remains the primary treatment 
modality, and prognosis is poor. 
 
Currently, there are cell lines that model these stages of drug resistance.  MCF7 
cells are a human epithelial mammary cell line that is ER positive and sensitive to 
tamoxifen and fulvestrant [9].  MCF7 cells require estradiol, the ligand for the ER.  
To create a cell line that modeled AI resistance, MCF7 cells were grown in 
ovariectomized nude mice, harvested and cultured in vitro as LCC1 cells.  This 
cell line does not require estrogen for growth or survival, however these cells still 
remain responsive to estradiol.  These cells remain sensitive to tamoxifen and 
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fulvestrant [10].  LCC1 cells treated with increasing concentrations of fulvestrant 
developed into a fulvestrant resistant and tamoxifen cross-resistant cell line, 
LCC9.  LCC9 cells maintained their estrogen independence [11].  MCF7, LCC1 
and LCC9 cell lines make excellent model systems to study drug resistance. 
 
A functional genomics approach to cancer drug resistance can connect genomic 
data with survival outcome (i.e. viability, apoptosis) to identify molecular 
determinants of resistance.  Gene regulation through small interfering RNAs 
(siRNAs) has previously been explored in drug sensitizing cancer screens [12, 
13].  This method is a global approach, which broadens the search space beyond 
the known genes/proteins involved in cancer related pathways.  siRNAs are 
synthetic 22 bp RNAs that are designed as the complement to a gene transcript 
and cause mRNA degradation that has been associated with depletion of the 
protein [14]. More recently, focused siRNA libraries have been successful in 
identifying novel resistance mechanisms and drug targets in cancer[15, 16]. 
Focused libraries are much smaller than whole genome libraries but offer an 
enriched set around a particular protein or pathway.  The smaller size of a 
focused library lowers the cost of screening, allows for deeper investigation 
through iterative runs and enriches for hits.  For these reasons, we hypothesized 
that a siRNA library enriched around the ER would be an excellent tool to 
understand AE/AI drug resistance in breast cancer.   
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Biological networks represent the complex interactions among proteins [17, 18].  
Drug resistance typically employs many mechanisms of escape through different 
protein complexes and signaling. I predicted a network centered on the estrogen 
receptor, related receptors and aromatase can elucidate these routes in AE/AI 
resistant breast cancer.  The seed proteins used to create the network are the 
two isoforms of the ER, ESR1 and ESR2, estrogen related receptors, ESRRA 
and ESRRG, and aromatase, CYP19A1.  As previously mentioned the ER 
isoform ESR1 is overexpressed in 70% of breast cancers diagnosed in women 
and is the target of AE.  ESR2, the other ER isoform, is a tumor suppressor.  
Loss of ESR2 expression is linked to tamoxifen resistance in breast cancer cell 
lines [19].   Estrogen related receptors ESRRA and ESRRG have no known 
ligand and cannot be pharmacologically inhibited like the ESR1. High ESRRA 
expression and activity is associated with poorer prognosis in breast cancer [20].  
In contrast, loss of ESRRG is associated with higher breast cancer grade, 
metastasis, recurrence and poor outcome [21].  CYP19A1 is the AI target and is 
essential in the synthesis of estrogen, the ligand of the ESR1.  By probing the 
network created around these five proteins with siRNA using the breast cancer 
drug resistant models, MCF7, LCC1 and LCC9, molecular determinants of 
survival were identified.   
 
This work has led to several publications and presentation in the field of cancer 
research: 
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Chapter 2: In silico Tools to Launch Protein interaction Analysis: Creating 
Focused Networks Around Proteins of Interest 
2.1 Introduction 
This chapter is adapted from Basic Methods in Protein Purification and Analysis 
[22].  I used the knowledge and skills I gained in writing this chapter about 
creating focused networks around key proteins to create a network focused 
around estrogen receptor signaling to identify and understand the molecular 
determinants of drug resistance in breast cancer cell lines.   
 
Wet bench-based approaches to identify and dissect interactions between a 
protein of interest and its partners are well-validated approaches that provide 
common points of entry into the study of new proteins of interest to a research 
group.  Within the past five years, it has become possible to take a 
complementary approach, which is based on the exploitation of the increasingly 
comprehensive databases available in the post-genomic era.  By combining 
information available in these in silico resources, it is becoming feasible to 
develop a relatively extensive network reflecting physical and functional 
interactions for any protein of interest.  Most of these resources do not require 
specialized knowledge of computer programming to be exploited by molecular 
biologists, while user-friendly programs such as Cytoscape [23] and Osprey [24] 
allow researchers to generate their own local resources for proteins of interest.  
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This chapter provides a step-by-step illustration of how to use open-access 
resources to develop a protein-targeted network that can be used to generate 
and test hypotheses. Figure 1 provides an overview of the steps to follow in 
constructing a network, as will be discussed in the following sections. For 
network construction, our primary tools will be protein-protein interaction (PPI) 
databases, canonical pathways databases, genetic interactions from model 
organisms, and microarray studies.  As a concrete example, we will use these 
resources to develop a network around a protein of interest, the pro-metastasis 
factor NEDD9 [25, 26].  As of 2008, approximately 75 published papers cite 
NEDD9 as a main or peripheral topic of study.  This is far fewer than for much 
studied proteins such as Rb (>4000), BRCA1 (~6000) and ERK1 (~8000), but is 
typical of many proteins of current biological interest.  
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Figure 1 Flow Chart for network construction. 
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As we discuss at the end of the chapter, network generation is useful in providing 
an interpretive context for direct purification experiments. The data in the network 
does not simply reiterate results that can easily obtained from direct reading of 
the primary literature, but provides a physical and functional interaction 
"landscape" that can serve as a valuable hypothesis generator for subsequent 
work.   Finally, although this article emphasizes the ability to generate a network 
based predominantly on in silico resources, we also discuss how all of the tools 
and resources described here can be used with a custom set of "seeds" derived 
from wet lab data.  
 
2.2 Collecting and visualizing data for a network. 
2.2.1 Terminology 
When working with networks, individual proteins are referred to as “nodes”, and 
the interactions between the proteins are called “edges”.  In Figure 2, we have 
created a simplified network to visualize these concepts.  In the diagram, 
NEDD9, BCAR1, SMAD3, CRK, GRB2, FYN, EGFR, SMAD4 and CREBBP are 
nodes, and the lines connecting the nodes to one another, are edges.  All the 
proteins that directly interact with a specific protein are called the “first neighbors” 
of that protein.  “Second neighbors” are all the proteins that directly interact with 
the first neighbors of the specific protein.  In Figure 2, NEDD9 is our starting 
protein of interest or "seed" (yellow), BCAR1, SMAD3 and CRK are the first 
neighbors of NEDD9 (orange) and GRB2, FYN, EGFR, SMAD4 and CREBBP 
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are the second neighbors (red) of NEDD9, which directly interact with the first 
neighbors (orange).   
 
Figure 2 Nodes, Edges, and Linkout functions in Cytoscape. See main text for 
details. 
 
2.2.2 Choice of Display Tools 
The first step of network assembly is to download and become familiar with the 
workings of one or more of several publicly available software packages for data 
management and display. The purpose of these programs is to provide users 
with tools to visualize gene/protein interaction networks, to map experimental 
data back onto the network for analysis, and to facilitate analysis by providing 
direct links to other Web-based resources.   
 
Which program to select as main platform for work depends on which features 
are regarded as most useful for a given project: each package has some 
advantages and disadvantages. Questions to keep in mind include the following:  
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1] Is it more valuable to have ease of use, or more tools to analyze the data? 
2] For visualization, how important are display aspects (e.g., multiple color tones, 
shading)? 
3] Will it be desirable to have multiple networks open at one time? 
4] For navigating among datasets, what options for selecting nodes are the most 
important (i.e., selecting individual nodes manually; by defined properties such as 
GO terms; by interaction confidence levels; etc.)? 
5] What options for import and export of tables, Excel files, and graphics are 
available?  
6] Can searches be done online (or do they require importation of very large files 
onto local computers)? 
7] How important will it be to be able to add customized information (i.e. specific 
links) or overlay additional information (such as GO categories, expression data, 
cell compartmentalization)? 
8] Is it important to include analytic tools to assess network topology? 
 
Available programs include IM Browser [27], Osprey [24], and Cytoscape [23].  
Among these, IM Browser was originally developed for use in managing 
Drosophila data, and to date has been most used in that context.  Osprey has a 
number of useful features: it has been made by professional software 
developers, allows seamless import from a very useful database, Biogrid [28], 
and works with genes designated by their common names. Comparative 
weaknesses of Osprey include the relative difficulty in selecting nodes in densely 
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displayed networks, the limited number of layout options, and the relative inability 
to add additional features.  For those starting out in network construction, 
Cytoscape is an extremely user friendly available in versions that run on both 
Mac and PC computers. In contrast to Osprey, Cytoscape has been made open 
source, by an active community of developers (www.cytoscape.org). While this 
community-based development process causes some difficulties (notably in 
program bugs), it has generally been extremely positive in creating a powerful 
resource. 
 
For getting started with Cytoscape, or to obtain information on how to use 
optional advanced tools in Cytoscape, a detailed manual can be freely 
downloaded from the resource Website.  Hence, our goal is not to provide 
exactly detailed instructions for network construction, but to discuss strategies. 
Cytoscape allows the user to import protein data files and export assembled 
networks in easily manageable file types such as tab delimited or Excel 
spreadsheet files.  Cytoscape has many tools that can be used interactively 
when viewing the network.  For example, right clicking a specific node will link to 
many different bioinformatics resources to find out more about a given protein.  
Figure 2 illustrates the LinkOut tool, which connects to an assortment of 
informative resources. In this example, the Entrez Gene option is being used to 
retrieve the Entrez Gene webpage for NEDD9: 4739 is the Entrez ID for NEDD9. 
Which links are available depends on how node IDs are imported and maintained 
in Cytoscape.  For instance, if protein lists are imported as Entrez ID numbers, 
  
 
 
15
only Entrez links can initially be used. If information form a different resource is 
desired, the node requires alternative annotation with the correct identifier for the 
alternative databases (tools for ID conversion are discussed in following 
sections).  
 
Cytoscape also makes it easy to collect, store, and display additional information 
on proteins and their interactions.  This information, termed node/edge attributes, 
can be used in visualization of the network.  For example, one simple option 
available in Cytoscape allows you to color nodes of specific subsets different 
colors, as used in Figure 2 to emphasize first (orange) and second neighbors 
(red).  While the Cytoscape package allows automatic generation of many 
attributes (e.g., based on network topology or gene ontology (GO) functions), 
there are some characteristics that user will want to add to the network that are 
unique to their interest in the network.  For these circumstances, Cytoscape 
allows the user to import node and edge attributes. For instance, several of the 
PPI databases provide PubMed IDs associated with reported interactions. Figure 
3 shows a PubMed link to the abstract of the paper in which a specific PPI was 
confirmed. To allow this, we create a hyperlink as an edge attribute to import into 
Cytoscape.  Next, we highlight a subset of our PPI network and viewed the 
details of the edge attributes by clicking on the “edge attribute browser.”  A single 
click on the hyperlink opens a web browser and displayed the PubMed abstract 
as shown in the bottom right corner of Figure 3.  
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Figure 3 Retrieving information about sets of nodes. In the Network window of Cytoscape, dragging a selection with the 
mouse arrow (dashed rectangle) will select nodes and/or edges, depending on the setting selected. In the example shown 
here, Cytoscape marks selected nodes in yellow, and selected edges in red. Any information, which researcher judges to 
http://www.ncbi.nlm.nih.gov/pubmed/9748319?ord...
  
 
 
17
be important or relevant to the project can be saved in Cytoscape as an 
"attribute", and will be shown in the Data Panel upon selection. This attribute can 
be an Internet link; in this case, clicking on it in the Data Panel will open a new 
browser window on a corresponding Web page. Here, Cytoscape automatically 
highlighted the edge selected in the Data Panel in green. 
 
2.2.3 Gathering and Merging Information 
Networks can combine multiple different classes of information, including PPIs, 
data from "expert systems", gene and protein expression data, and genetic 
interactions identified in multiple model organisms. How this data is combined 
depends on the goals of the project, and the richness of the data set available to 
select from, as discussed below.   Increasingly, as databases are populated from 
combined detailed and high-throughput studies, it is possible to construct a very 
rich landscape around a protein of interest (see Figure 4). In productively 
combining information from different resources, it will usually be necessary to 
perform ID conversions for each node.  Because of lack of standardization, gene 
information is recorded in varying ways in distinct databases, with genes denoted 
by terms varying from Gene ID (a number), symbol, or Refseq. Sometimes the 
identifiers can be unique to the database, but are not used as an identifier 
common to the scientific community, as discussed in the following example.  It is 
necessary to bring all nodes in the database to a common identifier system to 
apply tools to the entire network. 
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Figure 4 Options in combining data.  After the user becomes familiar with a 
visualization tool, data is imported from options including PPI databases, model 
organism-based functional interaction databases, and co-expression (e.g. 
microarray) databases, and pathway maps (expert knowledge). In building a 
resource, both "core" datasets, reflecting proteins linked to the network seed in 
many databases, and "context" datasets, reflecting proteins more distantly 
connected to the seed or only found in 1 or 2 databases, are generated.  How 
this data is used depends on the researcher's ultimate goal.  In option 1 (left), 
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only data found in multiple orthogonal datasets is selected, for example; this 
extreme option would be useful when working with a very well-known gene, to 
confine the list of targeted candidates to a reasonable size for mid-throughput 
experiments.. In option 2 (center), proteins found in multiple “core” datasets 
connecting to the seed are selected, and the intersections between the "context" 
datasets are added, to define an interaction sphere of high value candidates.  In 
option 3, right, all proteins linked to the seed by any of the search criteria are 
maintained as a resource that can be mined as needed to build context around 
high value proteins that emerge as linked to the seed. In this case, it may also be 
used to run the merged dataset through the STRING resource to potentially 
retrieve additional connections between the genes, based on orthogonal 
datasets.   
 
 
 
Gene/protein ID converters such as Clone/Gene ID Converter are very useful as 
a starting point for ID consolidation, and significantly expedite database 
construction [29]. These tools work with lists of gene IDs collected from a 
database and saved as simple Word or Excel files. However, frequently these 
tools cannot accurately convert all of the proteins in a list of interest: losing nodes 
to ID conversion is a common problem when merging information from 
databases using solely automated approaches. For example, many Entrez IDs 
are replaced or removed on a regular basis due to advances in knowledge, 
making it difficult for the curators of the gene/protein ID converters to keep up to 
date and thus, convert every gene/protein in a list. Hence, manual conversion for 
“orphan” IDs is often necessary.  
 
As an important caveat, the automated conversion is unlikely to “swap” one gene 
for another, a human being might be tempted to substitute commonly used 
names for given genes.  For example, NEDD9 is known to interact with the 
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protein CHAT/NSP3: however, the official name for this protein is SH2D3C (SH2 
domain containing 3C, Nsp3), with the symbol CHAT reserved for choline 
acetyltransferase. Another caveat that exists during ID conversion is that some 
gene symbols can signify completely unrelated genes in different species.  For 
example, when searching the gene symbol PKC in Entrez Gene, it is protein 
kinase C in Sus scrofa (pig) and in Apis mellifera (honeybee) but it is paroxysmal 
kinesigenic choreoathetosis in Homo sapiens.   The gene symbol for human 
protein kinase C is PRKCX, where "X" is an additional letter indicating the 
specific isoform of gene.  Hence, it is important to individually check results by 
reading gene descriptions and comparing number of genes in input and output 
lists when assembling the initial resource. 
 
In working with human proteins that have been the topic of little or no previous 
formal study, sometimes no hits will be found in initial database searches. In 
these cases, performing initial sequence-based searches to find homologs or 
likely homologs in other species can sometimes provide suitable "seeds" that can 
be used to find near neighbors. If necessary, homology searching can be 
sequence based, using standard NCBI resources such as BLAST; for most 
genes, the Homologene and Unigene functions will now readily identify likely 
orthologs across species. 
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2.3 PPI Databases 
As shown in Figure 1, identification of PPIs is a useful first step in network 
construction. Numerous PPI databases exist (Table 1), and several of these are 
overlapping in the information that they provide.  A graph comparing the number 
of interactions in each database is shown in Figure 5. Within each database, 
protein interactions are annotated with detailed information regarding the 
experimental data regarding the "report" of a protein interaction, facilitating 
judgment calls for inclusion or exclusion of any given interaction. For the NEDD9 
test case, we used the databases with the most interactions: BIND, BioGRID, 
and HPRD.   
 
Table 1 Bioinformatic Resources 
 
Protein-Protein 
Interactions 
  
The JCB Protein-Protein 
Interaction Website 
www.imb-jena.de/jcb/ppi/jcb_ppi_databases.html 
BIND bond.unleashedinformatics.com 
BioGRID www.thebiogrid.org 
HPRD www.hprd.org 
STRING string.embl.de 
DroID www.droidb.org 
Pathways 
Pathguide www.pathguide.org 
GenWay www.genwaybio.com/index.php 
KEGG www.genome.jp/kegg 
LINNEA Pathways www.invitrogen.com/site/us/en/home/LINNEA-
Online-Guides/LINNEA-Pathways.html 
 
Conversion Tools 
Clone/Gene ID Converter idconverter.bioinfo.cnio.es 
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FLIGHT flight.licr.org 
 
Visualization Tool 
Cytoscape cytoscape.org 
IM Browser proteome.wayne.edu/PIMdb.html 
Osprey biodata.mshri.on.ca/osprey/servlet/Index 
 
Other 
 
BIOCONDUCTOR www.bioconductor.org 
Entrez Gene www.ncbi.nlm.nih.gov/sites/entrez 
GEO www.ncbi.nlm.nih.gov/geo 
 
 
 
Figure 5 Numbers of interactions reported in protein interaction databases. 
Values represent statistics reported on each website (as of May, 2008), or in 
recent database-linked publications. 
 
 
 
The Biomolecular Interaction Network Database (BIND) archives protein, RNA, 
DNA, small molecule, carbohydrate and lipid interactions.  The interactions in this 
database span several taxonomies and are curated from both low and high 
throughput experiments.  As of 2005, BIND had ~180,000 interactions, and the 
site is updated daily with new interactions, but the official number is not provided 
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on the website [30].  This database had 4 first neighbors and 87 second 
neighbors for NEDD9 (244 interactions total) all derived from Homo sapiens.   
 
BioGRID, the General Repository for Interaction Datasets, is a collation of 
curated protein and genetic interactions from six different species, including 
Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster 
and Homo sapiens. It contains ~141,500 non-redundant interactions (as of June 
1, 2008) [28].  This database is updated monthly with new interactions, derived 
from both high-throughput studies and conventional focused studies. Taking only 
Homo sapiens interactions to identify first and second neighbors for NEDD9, we 
found 27 first neighbors and 402 second neighbors (429 nodes total), with 75 
edges for the first neighbors and 1806 edges in sum.  
 
The Human Protein Reference Database (HPRD) contains PPIs along with post-
translational modification data.  They have the most comprehensive collection of 
human PPIs of any database.  This database also has other features such as 
isoform and functional information, sub-cellular localization and disease 
association.   All of the data provided in HPRD has been curated by manually 
reading papers reporting in vivo and in vitro experiments. As of May 2008, HPRD 
has 38,167 interactions [31, 32].  This database identified 29 first neighbors and 
876 second neighbors for NEDD9, with a total of 5,779 interactions.   
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All data gained from these databases was imported into Cytoscape, by 
downloading the complete binary interaction files from BIND, BioGRID and 
HPRD (Figure 6).  These files can then be imported into Cytoscape and then 
used to create networks within Cytoscape.  It is practical to do this rather than 
using the web-browser interface for each isolated database, because we can 
customize one aggregated file to our needs, and then generate many focused 
networks containing tailored attributes.  The networks that we generate from the 
binary interaction files allow us to also retrieve the interactions between, for 
example, the first neighbors; the web-browser interface allows us only to retrieve 
the interactions between the protein of interest and its first neighbors, but not 
among the first neighbors.  First neighbors of NEDD9 were collected from each 
of these 3 imported files and in STRING, another PPI database that performs a 
search to gather interactions from several existing PPI databases and also 
performs PPI predictions.  These first neighbors from the 4 databases were 
merged together and then used as an input to find second neighbors from each 
of the 4 databases.  The second neighbors were collected and combined from 
the databases to complete the PPI portion of the network. 
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Figure 6 Assembly of different PPI datasets in Cytoscape.  First and second 
neighbors from HPRD, BIND, and BIOGRID are displayed. 
 
Some available databases are amalgamations of other existing PPI databases. 
For example, the Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING) contains approximately 1.5 million proteins from 373 species (as of 
May 1, 2008) and is freely available [2].  STRING gathers interactions from 
sources including BioGRID, DIP, MINT, KEGG, IntAct, Flybase and others (see 
[2] for complete list).  For a given species, STRING also includes its own 
algorithm-based predictions of interactions based on orthologous interactions 
observed in model organisms.  When querying for interactions of a protein(s) in 
STRING, the web interface allows for the selection of method(s) by which the 
interactions of your network will be generated (i.e. experimental, text mining, 
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orthologous predictions etc.).  This "metasearch", as compared to the direct 
search of the unique databases, is invariably easier and faster, and may pick up 
additional interactions: however, it can also miss some interactions.  It is up to 
the individual researcher to decide how comprehensively to search in defining a 
working network. 
 
We chose to use a strict criterion to gather the first and second neighbors of 
NEDD9 from STRING, only allowing interactions that have been experimentally 
verified in low throughput experiments (Figure 7).  We found 30 first neighbors, 
with 92 interactions among the 31 proteins.  Unfortunately, when converting 
these 30 proteins into Entrez IDs we lose 5 of them in the process.  In our 
STRING network first neighbor analysis we imported a table with 26 nodes and 
86 edges.  We used the same criteria but increased network depth parameter to 
2 when performing the analysis for the second neighbors.  After the ID 
conversion we had a combined total of 175 nodes and 720 edges for the first and 
second neighbors of NEDD9 in STRING.    In this case, we did not download a 
binary interactions file from STRING because we could retrieve the interactions 
between the first and second neighbors using the web-browser interface.   
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Figure 7 Screen shot, STRING search for NEDD9 interactors. Figure illustrates a 
simple network that was generated in a search in which only the parameter 
"experiments", reflecting protein-protein interaction information is considered.  
Other screening options ("neighborhood", "coexpression", etc) are shown.  
Values such as confidence interval allow weighting of recovered results to 
change certainty of displayed information. 
 
To complete the assembly of direct PPI information, we merged the first neighbor 
analyses from the 4 databases and came up with our First Neighbor Core, 33 
proteins and 133 interactions among them (Figure 8). It is possible to click 
directly on the line connecting two nodes, and directly recover information 
describing the source and data quality supporting the assignment of any given 
interactions. The merged second neighbor set developed from this core included 
922 proteins and 5375 interactions. Our options are to include this entire data set 
to the network, or to use it selectively in designing a working network. Either 
approach can be taken; in our work, we typically use the second neighbor set 
selectively to enrich biological processes of functional interest for NEDD9 
studies, as discussed below, based on convergence with orthogonal datasets. 
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Finally, in the analysis described here, we specifically searched for information 
regarding human NEDD9; many of the same databases contain additional 
information from other mammals and can often supplement human datasets. 
 
 
Figure 8 First neighbor core.  Highly validated nodes found to interact with 
NEDD9 in multiple PPI databases are shown.  Interactions among proteins within 
the group are also indicated; note some nodes are characterized by multiple 
cross-linkages, reflecting participation by group members in a signaling pathway 
(see Figure 13), while others are not, in the absence of additional information 
groups. 
 
2.4 Protein Complexes 
The composition of the protein complexes isolated using immunoprecipitation or 
TAP techniques also provides clues on potential interaction partners. Of the PPI 
databases, BIND and Intact provide information on protein complexes, BIND has 
a separate subdivision of the database. Intact has both binary and intercomplex 
interactions merged together (which makes a search for confirmed binary PPIs 
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more challenging in this database, if trying to separate these two categories). 
However, unlike the binary interactions reported in the previous examples, these 
data do not provide information as to whether interactions are direct or indirect. 
Hence, depending on the goal of the experiments, it is not necessarily a good 
idea to look for second neighbors of proteins retrieved as components of a 
complex. In addition, perhaps because of the difficulty of effectively annotating 
interactions involving a protein complex in the absence of set naming 
conventions, PPI databases sometimes miss protein complexes described in the 
research literature, making this data an underestimate of what is available via 
PubMed searches. Applying this approach to NEDD9, we find one complex 
described in the literature (BIND ID:144540). Most of the components of this 
complex were already known from a binary interaction search, but one new 
interaction, APC10, was added. 
 
2.5 "Canonical Pathways" 
 It is possible to continue expanding the networks around a protein of interest by 
searching for third neighbors in the PPI databases, but in practice, this produces 
such a large dataset as to remove utility; even the list of second neighbors is 
frequently unwieldy for generating hypotheses.  As a complementary approach, it 
is useful to matrix PPI data with information from “canonical pathway” databases 
that have been constructed either as free community resources, or as 
commercial products. The rationale in this approach is that while NEDD9 itself 
has a limited number of papers addressing its functionality, some of NEDD9’s 
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well-validated first neighbors have attracted significant previous interest. 
Resources that address these neighbors can identify functionally highly validated 
partners and upstream or downstream factors that are relevant to NEDD9, and 
might illuminate subsets of the second neighbor dataset of particular interest for 
specific biological processes. 
 
One comprehensive source providing a point-of-entry to signaling pathway 
databases is Pathguide, www.pathguide.org [33].  We initially directly searched 
for pathways that contained NEDD9 based on our knowledge of its involvement 
of specific biological processes (i.e., focal adhesion signaling), or alternatively of 
directly querying for NEDD9 in the search function of a more extensive group of 
databases.  These approaches did not identify a hit for NEDD9 in a search of 
over 25 different pathway databases.  However, from our initial PPI analysis, we 
knew that NEDD9 binds and is phosphorylated by SRC in the focal adhesion 
pathway, and that SRC is an important and relevant regulator of cancer 
metastasis. We therefore collected the nodes around SRC in the canonical focal 
adhesion signaling pathways from 3 databases to identify key proteins in these 
processes.  This approach was extremely productive.   
 
The three focal adhesion pathway sources that we used to build this network are 
KEGG Pathways [34] (Figure 9), reflecting the work of non-profit investigators, 
and commercial but publically accessible options such as GenWay Pathways, 
and Linnea Pathways. These (and many other) databases do not provide a file 
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containing all the binary interactions of the pathway.  Rather, nodes in theses 
pathways are initially captured as lists, and if desired, re-mining of PPI databases 
exploited to fill in the interactions among key nodes.  This step of creating the 
network can be quite time consuming if pathway databases of particular interest 
do not automatically provide a list of genes/proteins involved in the pathway 
(which is typical); it may be necessary to manually generate a list of 
genes/proteins in the pathway from the image available. Once a list is obtained, 
the gene symbols are converted to Entrez IDs using the Clone/Gene ID 
Converter, discussed above [29].  The pitfalls discussed above for automated 
and manual name conversion apply. For example, only ~66 percent of the genes 
from the Linnea Focal Adhesion Pathway were automatically converted, with the 
remainder requiring manual search for Entrez ID number. 
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Figure 9 Focal adhesion pathway map from KEGG.  Although NEDD9 is not 
found in this map, several of its high confidence first neighbors (e.g. FAK, SRC 
family kinases, p130Cas) are present: data is collected from functionally linked 
proteins. 
 
 
Once lists of genes and proteins from the three pathway programs have been 
converted to Entrez IDs, the datasets are merged as for PPIs.  For NEDD9, this 
identified 42 unique nodes.  Only 4 of the nodes were represented in all 3 focal 
adhesion pathways, representing the somewhat subjective biases underlying 
inclusion criteria of these pathways. However, 15 nodes were found in at least 2 
of the 3 pathways, suggesting a higher level of confidence in direct functional 
relevance.  Taking these 42 nodes and comparing them with the PPI first and 
second neighbor datasets, we find that 23 of the nodes are encompassed within 
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the second neighbor set, including 10 validated by at least two pathway 
databases. This suggests that these 23 nodes, and their interacting partners 
within the first and second neighbor set (Figure 10), might be a valuable set of 
genes to consider as a group when evaluating NEDD9 function in metastases. 
We add these 23 nodes to the NEDD9 "core" network of PPIs, bringing it to 57 
nodes.  A similar approach can readily be applied to other NEDD9 first neighbors 
associated with biological processes of particular interest. 
 
 
Figure 10 Pathway/PPI convergence in identification of NEDD9-relevant nodes.  
See text for details. 
 
 
2.6 Insight from Model Organisms 
Model organisms such as Saccharomyces cerevisiae, Caenorhabditis elegans, 
and Drosophila melanogaster have long been exploited because of their powerful 
genetics, which reveals functional relationships among proteins. Further, model 
organisms were the first to be exploited in high throughput two-hybrid [35-38] and 
mass spectrometry/complex purification [39, 40] studies. Proportionally, a much 
higher percentage of proteins are functionally annotated in these organisms than 
23 
15 
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PPIs 
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in higher eukaryotes, and very powerful curated databases (websites in Table 1) 
provide convenient sources for data retrieval. Because of evolutionary 
constraints, many important physical and functional relationships are known or 
likely to be conserved between lower and higher eukaryotes, and judicious 
compilation such interaction data across multiple species can increase the 
diversity of the nodes within a focused network.  The term interolog describes a 
protein-protein interaction that is common between species: this term was first 
proposed by [41], and has been developed in the following key studies [42-44].  
 
In exploiting these resources for our network construction, we note that NEDD9 
is one of a family of 4 proteins in mammals. This family has a single ancestral 
family member in Drosophila, and no clear relatives in Caenorhabditis or 
Saccharomyces.  We therefore first used the Drosophila Interactions Database 
(DroID) to find known interactions with the NEDD9 drosophila homolog, CG1212 
[27].  We excluded the human interolog prediction criterion but allowed all other 
methods of generating interactions, identifying 14 interactions among 15 unique 
nodes for the first neighbor analysis.  Of the 15 unique nodes, 5 had human 
homologs.  Expansion to DroID second neighbors yielded 340 total nodes for the 
CG1212 network.  Out of the 340 nodes, 170 have human homologs, as 
predicted by the Homologene search tool [45] from the FLIGHT database 
((Figure 11): FLIGHT [45] provides a central hub and many useful tools for the 
compilation of high-throughput Drosophila data).  
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Figure 11 The DroID tool in FLIGHT database.  See text for details. 
 
 
From the 170 homologs, 3 intersect with the first and 15 with the second 
neighbor human PPI dataset, and the rest are novel. One use of this data is 
clearly to provide an additional level of confidence that the 15 nodes in the 
second neighbor analysis are likely to be important for core NEDD9 gene family 
functions.  However, as noted above, there are 4 CG1212 related genes of 
paralogous but non-identical function in humans, and the biology of flies is non-
identical to that of humans.  Hence, the 155 novel nodes do not initially have as 
high confidence as directly relevant to NEDD9 function, but can be exploited as 
necessary to fill in interaction clusters of interest (discussed in sections 2.8, 9).   
 
2.7 Expression Data: Providing Context. 
For the human NEDD9 gene, the above approaches to network construction 
define a large sphere of potential functional interactions.  Most of these 
approaches do not offer insights as to whether the interacting proteins are 
dynamically co-regulated for specific biological processes or disease states.  It is 
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well known that biological networks generate coordinated changes in gene 
expression.   Hence, an important orthogonal dataset that can be used to inform 
the NEDD9 network describes gene and protein expression. 
 
Most journals now require authors to deposit microarray datasets for public 
access together with a minimal set of annotations (MIAME) [46]. Most published 
microarray datasets are publicly available in the ArrayExpress database [47] or in 
the Gene Expression Omnibus (GEO) [48, 49]. For data in the GEO database, 
the expression levels of genes in an experiment can be examined using the GEO 
Profiles tool [48], which searches for a gene of interest, and returns microarray 
datasets in which the mRNA was differentially expressed.  These results can 
then be used to identify mRNAs that have similar or opposite expression profiles 
[50]. In turn, these genes can be compared with the PPI proteins identified from 
other datasets. As these searches are done across all data sets, the results can 
suggest interesting model systems in which to functionally analyze your protein. 
 
Cancer researchers have an oncology specific database, Oncomine [51], in 
addition to the ArrayExpress and GEO international repositories.  Oncomine, 
which is free for non-profit researchers, provides easy searches to retrieve data 
sets in which a specific gene is differentiatlly regulated.  Entering NEDD9 in the 
search box, returns all cancer data sets in which it is differentially regulated at a 
defined p value threshold, with red and blue showing overall up-regulation or 
down-regulation respectively (see Figure 12a).  Each number represents the 
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number of studies for that specific tumor type and specific comparison type that 
show differential regulation of the target gene.  Choosing the number using the 
mouse leads to the data set. 
 
For illustrative purposes, we choose the Head and Neck study showing mild 
upregulation of NEDD9 in cancer vs. normal tissues.  We can then produce 
either a box plot or a cancer profile outlier plot (see Figure 12b).  It is clear that 
in this study NEDD9 is likely to be more highly expressed in tumors than in 
normal tissues. 
 
Genes that behave similarly to the target gene within a study can also be 
identified by using the Co/Ex option in Oncomine.  In this case, correlations are 
done to the target gene and genes that are highly correlated are reported.  This 
is not available for all studies in Oncomine, including that shown in Figure 11. 
Data for a second Head and Neck cancer study is available (see Figure 12c): in 
this example, the expression profile of NEDD9 was identified as similar to that of 
other mRNAs for genes including NRF1, IER3, and EST, and others: these gene 
Ids provide another orthogonal dataset that can be overlaid with the other 
predictive methods described here As a cautionary note, it is important to 
recognize the diversity in the quality of microarray data.   Many datasets were 
published when microarray technology first emerged, and both the core 
technology and analytic methodology have improved significantly in recent years.  
Re-analyzing older raw data using current methods is a good precaution if 
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considering inclusion of this data in a network. For statistical and informatics 
researchers, the R/Bioconductor package provides advanced tools for microarray 
data analysis, which can be automated to quickly retrieve, reannotate, and 
reanalyze data from GEO [52]. 
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Figure 12 Typical results from Oncomine.  These screenshots from the 
Oncomine resource show (a) the results of a search for NEDD9 in the database, 
(b) a Cancer Outlier Profile Analysis (COPA, [1]) projection for NEDD9 in the 
Oncomine database, using the Ginos Head and Neck tumor study as source, and 
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(c) use of the profiling function to discover genes with similar expression profiles 
to NEDD9 expression in the Toruner Head and Neck tumor study. 
 
 
 
2.8 The Assembled Network: Benchmarking to the NEDD9 Literature to 
Establish Network Utility  
One reason we selected NEDD9 (also known as HEF1 and CAS-L) as an 
example for this analysis is that our research group has been studying this 
protein for 15 years, and is extremely familiar with its biology [25, 26].  This 
knowledge allows us to examine the data generated through the resources 
described above, and to assess how effectively the main themes in NEDD9 
functionality have been captured in the in silico-generated network.  
 
Figure 13 shows one representation of an assembled NEDD9 network. In this 
representation, we have supplemented the data assembled as described above 
with two additional sets of information. In one case, we have used text-mining 
[53] (an option easily selected in STRING) to find gene names significantly linked 
to NEDD9 in the scientific literature. Given the current state of the art, this data is 
of lower confidence than the other data gathered as described above:  text-mined 
“interactions” with NEDD9 are indicated with dashed lines, and nodes are in paler 
colors. We have also included data from Aceview [54]. Aceview compiles 
information about genes based on co-expression, gene ontology (GO) 
classification, common domains, protein interactions, and other parameters: as a 
unique feature, it will make predictions about likely functional interactions based 
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on convergent datasets between a query protein and other proteins. We have 
included (pale green) cases where interactions predicted by Aceview (using all 
search criteria except protein-protein interactions) overlap with genes in the 
NEDD9 “second neighbor” sphere of interactors.  
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Figure 13  Composite NEDD9 network.  As described in the text, this network 
contains PPIs, networks, Aceview predictions, and text-mining.  
 
Well-established themes in study of NEDD9 have been (1) interaction with 
integrin-dependent signaling cascades that control migration, invasion, and cell 
survival; and (2) integration with multiple components of the TGF-β signaling 
machinery, relevant to cell differentiation control. Using the dynamic features of 
Cytoscape, we have gathered moved many of the proteins implicated in these 
NEDD9 activities to two separate clusters. Purple (top left) represents proteins 
involved in integrin-dependent signaling; yellow (center left) represents a cluster 
of TGF-β signaling effectors, including APC10 (identified from protein 
complexes). Besides demonstrating direct interactions of each of these proteins 
with NEDD9, it is easy to identify associations among the proteins within the 
functional group. It is also possible to readily display interactions that are known 
to be common between NEDD9 and its paralog, BCAR1/p130Cas (upper left, 
pink node; interactions shown in pink).  Clearly, many of the interactions with the 
integrin-dependent signaling set are conserved between NEDD9 and BCAR1, 
while interactions with the TGF-β signaling machinery are so far apparently 
specific to NEDD9. 
 
Interestingly, most of the protein interaction- and expert knowledge-based 
resources miss an important and well-documented NEDD9 interaction relevant to 
integrin signaling: that between NEDD9 and SRC. Similarly, the interaction of 
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NEDD9 with Aurora-A kinase/STK6, first reported in 2005 and connecting 
NEDD9 to pathways controlling mitosis and ciliary dynamics [55, 56], is not 
detected by STRING as a protein-protein interaction because of a gap in this 
database. However, Aceview clearly predicts the SRC and Aurora-A interactions 
(pale green), as well as a number of other potential interactions involving proteins 
such as ABI2, ITGAV, and others that show multiple interactions with NEDD9 
“first neighbors”.   
 
Taking Aurora-A as an example of particular interest, we then mined Aurora-A 
“first neighbors”, and compared this list to the set of genes already known to be 
included within the NEDD9 first neighbor/expert system network, or proteins 
predicted by text-mining to be NEDD9 partners. A large number of these Aurora-
A first neighbors were found to interact with one or multiple proteins that had also 
been connected to NEDD9, suggesting possible hypotheses for how NEDD9 
functions in different processes might be coordinated.  Finally (lower right, 
orange), a number of additional NEDD9 interactions are predicted by various 
means affecting a diverse set of cellular processes.  The density of interactions 
among proteins in the group suggests functional clusters (for example, among a 
group of text-mined proteins associated with inflammatory response).  However, 
proteins we have somewhat arbitrarily clustered within this “other” group may 
emerge with network updating as of particular interest for a new functional 
process, or specific scrutiny of one partner of interest (arbitrary e.g., MICAL) may 
identify new bridges connecting these “other” proteins more firmly to one of the 
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well-established NEDD9 functions. The network provides a dynamic resource to 
organize thinking and suggest new research directions. 
 
2.9 Using Network Tools to Analyze Custom, Experimentally Derived 
Protein Interaction Sets 
As of 2008, most molecular biologists and biochemists are not fully aware of how 
much high quality data is freely available to support studies of most proteins. 
Highly specialized skills are not necessary: the authors learned to use the 
applications described above based on 1-2 months of "playing" with online 
programs and following instructions accessible on free websites. Starting from 
the NEDD9 seed, we were able to generate a rich resource for protein 
interactions. Benchmarking to the available literature on this protein, these data 
mining efforts readily captured all direct interactions previously noted in the 
literature in a highly manipulable graphical display tool. The power of the 
approach emerged with the move towards second neighbors.  Because of the 
time requirements, it is clearly infeasible to perform literature-based search in 
adequate detail to perform direct neighbor analysis on all of NEDD9's first 
neighbors. However, by performing the simple steps to identify the NEDD9 
second neighbors and cross-referencing this data to other resources, we were 
able to identify a large set of candidate interacting proteins that might very 
reasonably be predicted to either also bind directly to NEDD9, or be closely 
connected to its function, and to identify high density interactions among proteins 
in this group. Based on publications in Pubmed, many of these (e.g. ABI2, AXL, 
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p53, or PML) have never been directly studied in the context of NEDD9 biology.  
However, the density of direct physical connections and in some cases co-
expression and other data available and clearly visible from the interaction 
modeling make it extremely likely that these proteins may indeed regulate or be 
regulated by NEDD9 in a relatively direct way.  These and other hypotheses 
remain to be tested. 
 
As of 2008, there is not yet a substitute for direct, wet bench experimentation to 
identify novel PPIs or probe pre-existing ones.  The approach described here 
does not work well with proteins that have attracted no prior research attention:  
for example, we chose two unstudied genes (LOC653352 and LOC63920), and 
used these to search for interactions in STRING, BioGRID, HPRD, and BIND, 
and retrieved no hits. However, the depth of our understanding of the cellular 
machinery has changed vastly in even the past decade, and there is no reason to 
believe the rate of change will decelerate. For researchers performing the protein 
purification techniques described in the first part of this book, parallel application 
of efforts to become facile in the informatics tools described briefly here will 
enhance data analysis in the present day, and poise projects to take full 
advantage of the discoveries of the coming decade. 
 
I learned how to create a focused network using the methods described while 
writing this article.  I then implemented these tools to create an estrogen 
  
 
 
46
receptor-centered network to probe using siRNA technology to identify molecular 
determinant of survival in drug resistant breast cancer cell lines.   
  
 
 
47
Chapter 3: Development and siRNA screening of an Estrogen Receptor-
Centered Network to understand Estrogen Independence in Breast Cancer  
 
3.1 Introduction 
Breast cancer is the most common cancer among women in the United States 
and is second overall in cancer related deaths [57].  Approximately 70% of newly 
diagnosed breast cancers are positive for expression of estrogen receptor alpha 
(ER) [58], a nuclear transcription factor that controls cell proliferation in large part 
by regulating gene expression.  More recently ER has been described as having 
additional functions, including the regulation of growth factor signaling. Anti-
estrogens (AEs) and aromatase inhibitors (AIs) are currently used to treat ER-
positive breast cancer in pre-menopausal and post-menopausal women, 
respectively, with each impairing cell proliferation and survival.  
 
The goal of this study is to identify new points of vulnerability in AE/AI-resistant 
breast cancers. A number of studies have demonstrated that changes in the 
proximal signaling networks to proteins targeted by drugs are particularly 
common sources of resistance to the targeting agent [12, 15].  I used in silico 
resources to develop a gene network centered on ER and related estrogen 
receptors and aromatase and then created and probed a siRNA library 
individually targeting genes in this network, to better understand the key 
mechanisms of estrogen independence and anti-estrogen resistance.    
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The collaborators for the work in the this chapter include Ilya Serebriiskii, Sandra 
Jablonski, Ionut Bebu, Wei Xu, Erica Golemis and Louis Weiner. 
 
3.2 Materials and Methods 
 
3.2.1 Design of an Estrogen Receptor-Centered Network 
An Estrogen Receptor (ER)-centered network was developed using the open 
source software tool, Cytoscape[23].  It is a tool used for visualization and 
analysis of networks.  Figure 14 is a screen shot from Cytoscape of a network 
with ESR1 and ESR2 highlighted in yellow.  All of the colored circles in the figure 
are proteins and are referred to as nodes when describing a network.  The 
interactions between the proteins are represented as the lines connecting the 
circles, referred to as edges.   
 
 
Figure 14 This is an image of Cytoscape network.  The nodes represent proteins 
and edges represent the interactions among the proteins.  Two of the seed 
ESR1 ESR2 
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proteins, ESR1 and ESR2, used to create the Estrogen Receptor-Centered 
network are highlighted in yellow. 
 
 
 
Creation of the ER-centered network began from 5 seed proteins: ESR1, ESR2, 
ESRRA, ESRRG and CYP19A1.  We selected these seed proteins because 
ESR1, ESR2, ESRRA, ESRRG are involved are involved in hormone receptor 
signaling and CYP19A1 is the gene symbol for aromatase, the target of AI. 
Bioinformatic databases were mined for protein-protein interactions (PPIs), 
protein complexes, members of canonical pathways linked with the 5 seed 
proteins and estrogen-responsive genes to complete the ER-centered network. 
These sources included BIND[30], BioGRID[28], DIP[59], HPRD[31, 32], 
IntAct[60, 61], MiMI[62], MINT[63], STRING[2], Biocarta[64], Linnea[65], Protein 
Lounge[66], STKE[67], Estrogen Responsive Genes Database[68] and literature 
searches[69, 70] (Table 2).   
 
Table 2 List of Bioinformatic Resources used to create ER-centered Network 
Complexes 
Intact[60, 61] 
PubMed literature search[69, 70] 
 
Estrogen Responsive Genes 
Estrogen Responsive Genes Database[68] 
 
Pathways 
Biocarta[64] 
Linnea[65] 
Protein Lounge[66] 
STKE[67] 
  
Protein-Protein Interactions 
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BIND[30] 
BioGRID[28] 
DIP[59] 
HPRD[31, 32] 
IntAct[60, 61] 
MiMI[62] 
MINT[63] 
STRING[2] 
 
 
 
Generally, data from each bioinformatic resource was added into the network 
based on a confidence level metric.  The data from each bioinformatic resource 
was divided into 2 categories (1) a high confidence core group of proteins and (2) 
a secondary group associated with a lower confidence level. All members of 
each high confidence core were included in the network while proteins from the 
low-confidence group were added only if they were found to overlap with at least 
1 of the other three data sources.  PPI databases were mined for first and 
second neighbors of the five “seeds.”  The first neighbors represent all proteins 
that are known to directly interact with at least one of the five seeds, and were 
considered the high confidence core. Second neighbors are proteins that directly 
bind to first neighbors of the five seeds and comprise the lower-confidence 
group.  All proteins found purified in a complex with one of the five seeds were 
added to the network.  Proteins designated by at least two different pathway 
sources as part of the ER signaling pathway belong to the high-confidence 
Pathway Core and all others represent the lower-confidence ER signaling 
pathway members.  The Estrogen Responsive Gene Database (ERGD) Core 
represents the high-confidence genes that at least 2 papers found the gene to 
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respond to an estrogen stimulus.  Proteins that fell in the intersections among the 
lower-confidence data from the PPIs, Pathway Analysis and ERGD were 
included in the network to complete the ER-centered network.   
 
3.2.2 Estrogen Receptor-Centered siRNA Library 
A siRNA library was custom-ordered from Qiagen in a 96-well plate format with 
each single well representing one of the 631 genes identified as part of the ER-
centered network.  Each individual well contained 2 pooled siRNAs, each with 
different target sequences for the same gene. siRNAs were resuspended in 
RNase free water at 1µM.  Qiagen-validated siRNA target sequences were 
preferentially picked when available. siRNAs targeting the ER-centered network 
genes were placed in 58 out of the inner 60 wells in eleven 96-well plates. The 
remaining two inner wells and outer 36 wells were reserved for controls. 
 
3.2.3 Cell Culture and Reagents 
HFF1, LCC1, LCC9, and MCF7 cell lines used in these studies were either 
currently maintained in the laboratories or obtained from the Tissue Culture 
Shared Resource at Lombardi Comprehensive Cancer Center, Georgetown 
University.  Cell lines were maintained at 37°C and  5% CO2 in conditions 
described in Table 3.  
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Table 3 Cell lines and Media 
Cell Line Media 
MCF7 
IMEM 5% CCS 
1nM Estradiol 
LCC1 IMEM 5% CCS 
LCC9 IMEM 5% CCS 
HFF1 DMEM 15% FBS 
 
 
3.2.4 Cell Viability Assay 
 
Cells were reverse transfected on day 0 with a total of 100.5µL of volume in each 
well.  After 24 hours, 100µL of media was added for a total volume of 200.5µL.  
144 hours later, 20 µL of 1:1 mixture of Cell Titer Blue (CTB) from Promega and 
Hank’s Buffered Salt Solution (HBSS) was added to each well and incubated for 
an optimized time interval between three and five hours before reading out the 
results using the EnVision Multilabel Plate Reader (PerkinElmer).  This viability 
assay measures the metabolic activity of the living cells to convert resazurin to 
the fluorescent metabolite resorufin as an estimate of the number of viable cells.  
Fluorescence is recorded at room temperature using an excitation filter at 570 
nm and an emission filter at 590 nm. 
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3.2.5 Screen Optimization 
 
3.2.5.1 Reverse Transfection and Reagent Selection 
Several reverse transfection reagents were tested in Costar 96-well plates for 
each cell line according to manufacturers’ instructions.  Transfection reagents 
tested included: DharmaFECT (DF) 1, DF 2, DF 3, DF 4 from Dharmacon, 
HiPerFect from Qiagen, RNAiFect from Qiagen, RNAiMAX from Invitrogen and 
siPORT from Applied Biosystems.  Cells were seeded at densities that resulted 
in 80% confluency 144 hours post transfection (see Supplemental Table 3).     
We used two controls from Qiagen: All-Star Negative control (NEG), a non-
silencing siRNA with no known homology to a mammalian gene, and All-Star 
Death control (DEATH), a combination of several siRNAs targeting genes 
essential for cell survival, to assess the transfection reagents.  NEG and DEATH 
siRNAs from Qiagen were transfected at 20nM and changes in cell viability using 
Cell Titer Blue (Promega) with each transfection reagent were assessed 144 
hours post transfection.  An optimal transfection reagent for each cell line was 
selected based on three criteria: (1) transfection reagent alone had minimal affect 
on cell viability, (2) transfection reagent plus NEG had minimal affect on cell 
viability and (3) transfection reagent plus DEATH greatly reduced viability 
compared to NEG, DEATH/NEG ≤ 0.2. 
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3.2.5.2 Moderate Controls Selection 
Moderate controls, genes whose knockdown moderately reduce cell viability, 
were selected for LCC1 cells.  Six siRNAs that partially reduced cell viability in 4 
different cell lines identified from previous siRNA screens (data from Golemis and 
Godwin labs from Fox Chase Cancer Center, not published) were evaluated for 
their affect on cell viability as a ratio compared to median value of NEG controls 
for LCC1 cells.  These experiments were set up as described in section 2.2.5.1 
using the transfection reagent siPORT. 
     
3.2.5.3 Z’-factor 
Z’-factor is an established measure used in screening to assess the dynamic 
range and variability of the assay.  A z’-factor is computed from the mean and 
standard deviation of the positive and negative controls Figure 15.  Typically, a 
Z’-factor above 0.4 is acceptable to move forward with screening[71].  All-Star 
Negative (NEG) and All-Star Death (DEATH) controls from Qiagen were reverse 
transfected (section 2.2.5.2) to establish Z’-factors to assess viability assay 
quality before screening MCF7, LCC1, LCC9 and HFF1 cell lines.  Viability was 
measured using Cell Titer Blue (Promega) as described in section 2.2.4.  There 
were 43 data points for each Z’-factor experiment for NEG and DEATH controls 
respectively.  
 
 
  1 
3	
  3	
|
|
 
  
 
 
55
Figure 15 Z’- factor equation used to assess the quality of an assay for 
screening.  Where SD
 
is the standard deviation and MEAN is the arithmetic mean 
of the annotated controls.   
 
 
 
3.2.6 Screening 
ER-centered library screens were carried out in duplicate using MCF7, LCC1, 
LCC9 and HFF1 cell lines.  Cells were seeded in 96 well plates at a density that 
resulted in a final well confluence of approximately 80%.  Cells were reverse 
transfected as described in 2.2.5.2.  There were 22 total experimental plates per 
screen for each cell line.  There were 11 total ER library plates with 631 siRNAs, 
and each siRNA corresponded to a different gene in a separate well, placed in 
the inner 60 wells of 96-well plates.  From each of 11 ER Library plates 2 
replicates plates were produced (11 library plates x 2 replicate plates/library plate 
= 22 plates).  Twenty-four hours post-transfection, 100 µL of media was added to 
each well and viability was measured at the end of the assay, 144 hours, as 
described in section 2.2.4.  
 
 
3.2.7 Screen Analysis 
The viability of each targeted gene and control was calculated by normalizing to 
median fluorescence value of 14 non-silencing controls (NEG) on the plate.  The 
normalized DEATH viability was required to be <0.2 to consider the screen 
results interpretable.   
 
 
  
 
 
56
3.2.8 Validation 
Hits identified by a loss of 50% viability following siRNA knockdown in the 
screened cell lines underwent validation studies. For each hit, four different 
siRNAs (Qiagen) targeting the same gene were subsequently tested in individual 
wells. Two out of the four siRNAs possessed the same target sequences as the 
siRNAs in the screen, when available.  The other two siRNAs possessed new 
sequences, with priority placed on validated sequences by Qiagen when 
available.  Cell lines were screened as described above using the deconvoluted 
siRNA targeting candidate genes identified in the initial screening studies.  A 
putative hit passed validation, if at least two out of four of the siRNAs tested 
reduced cell viability by at least 50%.  Hits in LCC1 cells as well as in LCC9, 
MCF7 or HFF1 cells were validated in LCC1 cells, otherwise, hits were validated 
in the identifying cell line. 
 
For the hits validated by siRNA, quantitative reverse transcriptase polymerase 
chain reaction, qRT-PCR was carried out to evaluate the gene knockdown.  72 
hours after transfection of MCF7, LCC1 or LCC9 cells grown in 96-well plates, 
total RNA were extracted cDNA were synthesized with a Cells-to-CT kit (Life 
Technologies, CA). Quantitative RT-PCRs were performed on ABI PRISM 7500 
Fast Real time PCR detection system (Applied Biosystems). The relative 
expression levels were calculated with the comparative Ct method.  Yongwei 
Zhang performed the qRT-PCR experiments. 
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3.3 Results 
 
3.3.1 Estrogen Receptor-Centered Network 
We hypothesized that loss of estrogen dependence would reflect an altered 
cellular requirement for genes closely linked to core genes regulating estrogen 
response, a 631 estrogen receptor-centered network was developed around 5 
seed proteins relevant to estrogen signaling: the estrogen receptor genes ESR1 
(ERα) and ESR2 (ERβ), the estrogen-related receptors ESRRA and ESRRG, 
and CYP19A1 (aromatase) (Figure 16).  For network construction, data for each 
of the 5 seeds was initially collected from public archives reporting protein-protein 
interactions (PPIs), association in protein complexes, curated pathway 
information, and estrogen-responsive genes. PPI databases were mined for first 
and second neighbors of the 5 seed proteins.  248 “first neighbors", defined as 
proteins that directly interacted with a seed protein based on experimental data, 
constituted a high confidence core, and were all included in the PPI dataset. 30 
proteins reported in the literature [69, 70] as in a complex with ESR1, ESR2 or 
ESRRA (but for which it is not known whether they are in direct physical contact 
with the seeds) were also included in the ER-centered network as a high 
confidence core.  The Biocarta [64], Linnea [65], Protein Lounge [66], and STKE 
[67] databases report ER signaling interactions. 44 proteins reported in at least 
two of these databases as associated with ER signaling were included as a 
pathway core. The Estrogen Responsive Gene Database (ERGD) [68] core lists 
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38 high confidence genes reported in at least 2 papers as manifesting a change 
in transcriptional response to an estrogen stimulus.  Beyond these high 
confidence cores, which in sum contributed 308 genes to the ER-centered 
network (Figure 17), an additional 323 genes were included based on their 
occurrence in at least two lower confidence sets (comprising 5592 second 
neighbors (interactors with one of the first neighbors), 290 additional genes from 
ER pathways and a lower confidence set of 310 estrogen-responsive genes from 
the ERGD).  A list of the 631 genes in the ER-centered network and 
bioinformatics source(s) of each component is presented in Appendix 1. 
 
 
Figure 16 The five seed genes from which the ER-centered network was derived 
and the protein-protein interaction among them[2]. 
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Figure 17 The Venn diagram shows the overlap among the high confidence core 
data sets included from bioinformatics resources in ER-centered network.   
 
 
 
Analysis of the proteins in the ER-centered network reveals the majority (97%) of 
the proteins in the ER-centered are a first or second neighbors of the 5 seed 
proteins.  Of those proteins, 32% and 34% are also associated with the ERGD 
and pathway datasets, respectively.  Minimal overlap was found between three 
or more of the informatics data types used to create the ER-centered network 
(Figure 18).   
 
Protein Protein 
Interactions (248) 
Pathway (44) 
Complexes (30) 
Estrogen 
Responsive Genes 
Database (38) 6 21 
0 0 
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Figure 18 A Venn diagram showing the final count and overlap from the 4 types 
of bioinformatics resources mined to create the ER-centered network.  The 
majority of proteins in the ER-centered network are a first or second protein-
protein interaction neighbor of the 5 seed proteins from which the network was 
created.   
 
 
 
3.3.2 Optimization 
Optimization is essential in preparing for any medium-throughput screening 
experiment.  Noise and variability are common drawbacks in the analysis of large 
“omic” data sets in biology.  Reducing variability during the assay development 
stage will improve the quality of the data set collect from screening.  Specific to 
the aims of this study three elements needed to be determined before conducting 
a siRNA screen: selection of (1) a lipid transfection reagent, (2) moderate 
controls and (3) establishment of an assay Z’-factor.   
Protein Protein 
Interactions (613) 
Pathway (238) 
Complexes (30) 
Estrogen 
Responsive Genes 
Database (232) 194 206 
18 6 
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3.3.2.1 Transfection Reagent Selection 
To identify an effective transfection reagent, several different lipid based 
transfection reagents were tested for their ability to reverse transfect MCF7, 
LCC1, LCC9 and HFF1 cell lines.  Assessment of the reagents was based on the 
viability measurement using NEG and DEATH siRNA controls.  Below, Figure 19 
show results of transfection reagents tested for the MCF7 cell line.  RNAiMAX 
was chosen as the best transfection reagent for the MCF7 cell line since it 
moderately reduced cell viability when transfected with NEG siRNA and greatly 
reduces cell viability when transfected with DEATH siRNA. This reagent had a 
minimal effect on cell viability with the lipid alone and in combination with the All-
Star Negative control compared to untreated cells.  Furthermore, at least an 80% 
reduction in cell viability was observed with All-Star Death control relative to the 
All-Star Negative control when cell-seeding density was adjusted for toxicity from 
the transfection reagent alone.  A summary of cell seeding density and assay 
reagents used for each cell line is outlined in Table 4. 
  
 
 
62
 
Figure 19 Viability assay showing the effects of transfection reagents, 
transfection reagents plus positive (DEATH) or negative (NEG) controls on MCF7 
cells to select the most appropriate reagent for siRNA screening.  RNAiMAX was 
selected as the best reagent to reverse transfect siRNAs into MCF7 cells.  Cell 
seeding density was further optimized to account for cellular toxicity caused by 
the transfection reagents to establish a larger dynamic range. 
 
 
 
Table 4 Cell lines, seeding density and corresponding transfection reagents 
Cell Line Seeding density  
cells/well 
Transfection 
reagent 
MCF7 7,000 RNAiMAX 
LCC1 2,000 siPORT 
LCC9 2,000 siPORT 
HFF1 8,000 Dharmfect 3 
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3.3.2.2 Moderate Controls Selection 
siRNAs moderately effecting cell viability were established for inter-plate 
variability assessment during screening. Six siRNAs that moderately reduced cell 
viability in 4 different cell lines (data from Golemis Lab and Godwin Lab, not 
published) were knocked-down in LCC1 cells and the effects on cell viability were 
measured.   siRNAs for genes GRB14 and AP2A1 were selected for their ability 
to modestly reduce cell viability in LCC1 cells (Figure 20) and then tested as 
moderate controls for MCF7, LCC9 and HFF1 cells (Figure 21).  
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Figure 20 Selection of moderate controls for siRNA screening in LCC1 cells. 
Viability is shown as a ratio of the median value of the NEG controls.  GRB14 
and AP2A1 were selected as moderate controls to assess assay quality during 
screening. 
 
 
 
Figure 21 Viability after siRNA knockdown of moderate controls used to assess 
quality of screens in LCC1, LCC9, MCF7 and HFF1 cell lines.  Viability is 
reported as a ratio of NEG.  GRB14 and AP2A1 moderately reduced viability in 
the cell lines while DEATH was used as a positive control in all screens.   
 
 
 
3.3.2.3 Z’-factor 
During the optimization portion of the screening process, Z’-factors were 
established for all cell lines screened against the ER-centered siRNA library.  A 
Z’-factor is tool used to asses the quality of an assay for high throughput 
screening.  It is a measurement that assesses the dynamic range and variability 
of the assay.  An ideal assay has a large dynamic range and minimal variability. 
Shown in Figure 22 below are the dot plot results from the viability experiments 
  
 
carried out in MCF7, LCC1, LCC9 and HFF1 cells to compute the Z’
dynamic range and variability can be visualized in the plots; the Z’
are listed below each graph.  
acceptable value of 0.4.  
Figure 22 Dot plots show viability for NEG and DEATH controls for each cell line 
screened: LCC1, LCC9, MCF7 and HFF1.  Z’
graph for each cell line.  
 
 
 
3.3.3 Screening Results
To compare the cellular requirement for genes in the ER
in the context of decreased estrogen dependence and increased anti
resistance, we used an siRNA library ta
The Z’-factor values all exceed the minimum
 
-factor values are written below the 
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network to screen four cell lines: MCF7, LCC1, LCC9, and HFF1.  MCF7 is an 
estrogen-dependent breast adenocarcinoma cell line sensitive to treatment with 
the AEs tamoxifen and fulvestrant. The MCF7-derived cell line LCC1 was 
selected in vivo for estrogen-independence, which commonly reflects AI 
resistance, but remains sensitive to tamoxifen and fulvestrant. LCC9, further 
derived by selection from LCC1 cells, is resistant to both tamoxifen and 
fulvestrant [11, 72].  Human foreskin fibroblasts (HFF1) do not depend on 
estrogen signaling, and provided a control for non-specific inhibitors of cell 
viability. Table 5 summarizes the estrogen and AE sensitivity of each cell line 
screened. 
 
 
Table 5 Sensitivity of cell lines to estrogen and anti-estrogens 
 
Cell Line Estrogen  Tamoxifen Fulvestrant 
MCF7 Dependent Sensitive Sensitive 
LCC1 Independent Sensitive Sensitive 
LCC9 Independent Cross-resistant Resistant 
 
 
 
The ER-centered siRNA library was reiteratively screened two times in the 4 cell 
lines. Analysis of primary hits indicated that LCC1 and LCC9 were significantly 
more susceptible to loss of viability following depletion of ER-centered network 
genes than were MCF7 or HFF1 cells, as observed in the screen distribution 
graph of Figure 23. 
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Figure 23 Viability distribution plots for cell lines screen against the ER-centered 
siRNA library. 
 
 
 
3.3.4 Validation 
We selected a subset of the results from the LCC1, LCC9, MCF7 and HFF1 
screens for further investigation.  Use of a biological cut-off of 50% viability or 
less identified 190 candidate hits for the LCC1 cells, 117 for LCC9 cells, 9 for 
MCF7 cells and 1 for HFF1 cells (Figure 24). Validation of hits obtained in LCC1 
or LCC9 cells was performed using transfection of deconvoluted siRNAs and 
confirmation of gene depletion by quantitative reverse transcriptase-polymerase 
chain reaction (qRT-PCR) (Figure 25).   
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Figure 24 Hits from ER-centered library screens in MCF7 (9), LCC1 (190), LCC9 
(117) and HFF1 (1) cells that reduce viability by more than 50% and were 
selected for further validation.   
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Figure 25 Efficiency of gene knockdown for siRNAs of validated hit genes. 
Quantitative RT- PCR showed depletion of most hit genes 72 hours after 
transfection in MCF7 (top), LCC1 (middle) and LCC9 (bottom) cells with duplex 
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siRNAs. Data were normalized to mRNA level in negative siRNA-transfected 
cells.  Experiments performed by Yongwei Zhang. 
 
 
 
Following validation, 85 genes were confirmed as potentially important for 
viability in LCC1 cells, 65 in LCC9 cells, and 3 in MCF7 cells; of these, 49 were 
common to LCC1 and LCC9, which included 3 also important in MCF7 cells 
(Figure 26). Focusing on the genes required in LCC1 and/or LCC9, we assessed 
if these genes selectively derived from specific categories of input to the ER-
centered network. This analysis indicated that this set was enriched for siRNAs 
targeting genes that either interacted directly with the 5 ER-centered network 
seeds, or included estrogen-responsive genes.  
 
 
Figure 26 Validated hit results from at least 2 out of four individual siRNAs 
recapitulating the phenotype observed during initial screens.  Overlapping hits 
were validated in LCC1 cells otherwise; hits were validated in the hit-identifying 
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cell line.  Of the over 200 genes selected for validation 101 gene hits were 
confirmed, including 49 genes that reduce viability by more than 50% in both 
LCC1 and LCC9 cells. 
 
 
 
3.4 Discussion 
In this investigation, an ER-centered network was developed using bioinformatics 
tools to provided an enriched network to probe for the purpose of better 
understanding estrogen independence and AE resistance.  Assay conditions 
were developed and led to an optimized assay with qualities sufficient to detect 
changes in viability in a mid-throughput screen environment.  A siRNA library 
targeting the 631 genes in the ER-centered network was used to screen cell 
lines, MCF7, LCC1, LCC9 and HFF1, with unique sensitivity profiles to estrogen 
and AE.  These screens led to the identification of 101 validated hits that reduce 
viability in at least one of the cell lines.  
 
Creating an ER-centered network from several bioinformatics resources was 
essential to ensure the inclusion of all proteins involved cellular ER activity.  At 
the time of development in 2008, as many bioinformatics data types relevant to 
the ER signaling were mined for the creation of the ER-centered network.  
Protein-protein interaction, protein complexes, pathways and the Estrogen 
Responsive Genes Database were identified as sources with ER cellular activity 
and were used to develop the ER-centered network.   
 
  
 
 
72
We set a goal of creating a network made up of approximately 500-1000 nodes.  
A network of this size would allow for cost-effective iterative screening of a siRNA 
library with many breast cancer cell lines.  In addition, the network would be 
enriched with proteins functionally linked to ER activity, which increases the 
likelihood of positively identifying hits. siRNA libraries of similar size have been 
used to identify key proteins involved in cancer drug resistance and treatment[15, 
73].  In order to achieve a network of this size, a method was used to select the 
genes or proteins associated with ER cellular signaling that were of a higher 
confidence and then to take the intersection among the lower confidence groups 
of the different bioinformatic sources.  This approach was especially helpful to 
strategically select second neighbor protein-protein interactions of the 5 seed 
genes, which exceeded over 5,000 members.  Given this information, it was not 
surprising that the majority (97%) of ER-centered network is a first or second 
neighbor of the 5 seed genes.  Interestingly, there was little overlap between the 
next two largest contributing groups to the ER-centered network, Pathways and 
Estrogen-Responsive Genes Database.   
 
Before the siRNA screens could commence, transfection conditions and viability 
assay optimization was necessary to confirm the quality of the assay for mid-
throughput screening.  Each cell line required testing for the optimal reverse 
transfection reagent.  When selecting a transfection reagent it was important to 
select a reagent that had minimum effect on the survival of the cells when 
transfected with the negative control and a decrease in viability of more than 80% 
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with the positive control.   Three different transfection reagents were used to 
transfect the four cell lines screened.  LCC1 and LCC9 were transfected using 
the same reagent siPORT, however the parental line, MCF7, required a different 
reagent for effective reverse transfection.  Optimizing the transfection reagent 
and in parallel adjusting the cell seeding density is integral for establishing a 
large dynamic range.  Variability and a dynamic range are assessed as part of 
the statistical parameter the Z’-factor, a measure ranging from 0 to 1 used to 
assess the quality of an assay for high throughput screening.  Low variability and 
a large dynamic range are part of what makes the Z’-factor value within the 
acceptable range for high throughput screening, greater than 0.4.  LCC1, LCC9, 
MCF7 and HFF1 cell lines all achieved Z’-factor values above 0.6.  In addition to 
optimizing the positive and negative controls for the siRNA viability screen, we 
added controls that moderately effected viability in the cell lines screened.  These 
controls were designed into the screen to help assess the quality of screen and 
trouble shoot any issue that may arise.   
 
The ER-centered siRNA library was reiteratively screened with the LCC1, LCC9, 
MCf7 and HFF1 cells.  Viability was calculated as a ratio of the median of the 
negative controls on each experimental plate of the screen.  All controls were 
reviewed as viability ratio and the positive control was required to reduce viability 
by more than 80%.  The results from these screens revealed that the ER-
centered network contained many proteins essential for the survival of estrogen 
independent breast cancer cells regardless of AE sensitivity.  The viability of both 
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LCC1 and LCC9 cells were more sensitive to the knockdown of the genes in the 
ER-centered network compared to the parental, estrogen dependent MCF7 cell 
line and normal-like HFF1 cell line.  Making a biological cutoff at 50% viability 
resulted in over 100 genes essential to cell survival in LCC1 and LCC9 cells and 
less than 10 in MCF7 and HFF1 cells.   
 
A putative hit was defined as a greater than 50% reduction in viability following 
gene depletion in any of the four cell lines screened and this set was selected for 
validation.  Confirmation of the phenotype observed included testing 4 individual 
siRNAs per gene and subsequently, qRT-PCR for the putative hits found in 
common between the LCC1 and LCC9 cells.  Validation resulted in 49 hits 
shared between LCC1 and LCC9 cells and three of those hits were also hits in 
MCF7 cells.   
 
Of these validated hits a few have previously been reported to be involved in 
breast cancer.  For example, insulin receptor substrate 1, IRS-1, is linked to 
acquired estrogen independence in vitro when overexpressed in MCF7 cells[74].  
The activation of IRS-1 promotes cell survival through activation of PI3K/AKT and 
RAS/MAP kinase pathways [75, 76].  IRS-1 depletion reduces cell survival in 
estrogen independent LCC1 and LCC9 cell, probably due to the lack of activation 
of these pathways.  Additionally, pharmacologically targeting the proteasome in 
combination with fulvestrant in AE resistant breast cancer cells was shown to 
reduce cell survival.  The use of this combination to treat estrogen independent 
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breast cancer was suggested but not explicitly shown [77].  Since three of the 
validated hits from the ER-centered screen are proteasomal subunits, this 
indicates that the sole use of proteasomal inhibitors may be sufficient to treat 
estrogen independent breast cancer. 
 
The relevance of other hits to estrogen independent breast cancer is less clear. 
NR2F1 is a nuclear receptor transcription factor that forms a heterodimer with the 
ER in a protein complex at DNA binding sites.  When bound in a complex, 
NR2F1 enhance transcriptional activity of the ER in both and estrogen dependent 
and independent manner.  While estrogen-dependent transcriptional activity has 
been reported in breast cancer cells, estrogen independent transcriptional has 
not [78, 79].  The knockdown of NR2F1 in estrogen independent breast cancer 
cell lines likely disrupts ER transcriptional activity promoting cell proliferation.  
Further experimentation is necessary to prove this hypothesis.  Cysteine-rich 
angiogenic inducer 61, CYR61 is overexpressed in 30% of triple negative breast 
cancer (ER-, PR-, HER2) and induces tumorigenesis and angiogenesis [80].  We 
show for the first time that CYR61 expression is essential for cell survival in 
estrogen independent breast cancer cell lines.  The validated hits POLR2A, 
POLR2B and POLR2C are subunits of DNA-dependent RNA polymerase II (RNA 
pol II), which transcribes protein-encoding mRNA [81].  MED1, a protein that 
mediates interaction between the RNA pol II and ER during transcription, is 
overexpressed in tamoxifen resistant breast cancer cells [82].  Targeting the RNA 
pol II has proven to be challenge due to the toxicity of drugs developed [83].  
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Development of more tolerable drugs will make the RNA pol II a promising drug 
target for estrogen independent breast cancer. 
 
The ER-centered library contains many genes essential to the viability of 
estrogen independent breast cancer cell lines, LCC1 and LCC9 compared to the 
parental cell line MCF7 and normal-like cell line HFF1.  Further investigation is 
necessary to determine if this observation is true for all estrogen independent cell 
lines.  If this is more broadly applicable to lack of estrogen sensitivity, then 
understanding changes in cellular signaling and how cellular viability is being 
alter (i.e. apoptosis or reduced proliferation) will be important while examining 
these proteins as putative drug targets.  
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Chapter 4: Characterization of Estrogen Independent Pro-Survival Gene Set 
 
4.1 Introduction 
 
De novo and acquired resistance to current endocrine therapies is a major issue 
for the treatment of breast cancer.  The mechanisms underlying endocrine 
therapy resistance are poorly understood.  Woman who are post-menopausal are 
effectively treated with AI that block the synthesis of estrogen, the ligand of the 
estrogen receptor, however, resistance to these drugs occur in many women.  
Mechanisms of resistance are poorly understood and there is a need for novel 
targeted therapeutics for this subset of women to inhibit tumor growth.  In chapter 
2, I identified a group of putative drug targets from siRNA screening of an ER-
centered library for ER-positive breast cancer that no longer requires estrogen for 
survival, estrogen independence.   
 
In this chapter, I explore a representative gene set of the 49 genes identified as 
essential to the survival of estrogen independent LCC1 and LCC9 cells. I refer to 
the representative 25 genes as the estrogen independent pro-survival (EIPS) 
gene set.  These genes were selected to represent the range of viability based 
on the 49 validated genes, from 0 - 0.49.  The broader applicability of this gene 
set using a larger set of breast cancer cell lines that represent different levels of 
AE and AI resistance is shown.  In addition, cellular signaling is explored using 
cellular assays and network tools after gene depletion.   
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Collaborators for the work presented in this chapter include Yongwei Zhang, 
Sandra Jablonski, Ilya Serebriiskii, Joseph Murray, Erica Golemis and Louis 
Weiner. 
 
4.2 Materials and Methods 
 
4.2.1 Cell Culture and Reagents 
BT474, HFF1, LCC1, LCC9, MCF7, MCF10A, MDA-MB231, T47D and T47Dco 
cell lines used in these studies were cell line currently maintained in the 
laboratories or from the Tissue Culture Shared Resource at Lombardi 
Comprehensive Cancer Center, Georgetown University.  Cell lines were 
maintained at 37°C and 5% CO 2.  For information on medium see Table 6. 
 
Table 6 Cell lines and culture conditions 
Cell Line Media 
MCF7 IMEM 5% CCS 1nM Estradiol 
LCC1 IMEM 5% CCS 
LCC9 IMEM 5% CCS 
T47D IMEM 5% CCS 1nM Estradiol 
T47Dco IMEM 5% CCS 
BT474 IMEM 5% CCS 1nM Estradiol 
MCF10A DMEM/F12 5% HS  
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HFF1 DMEM 15% FBS 
MDA MB 231 Leibovitz's L-15 10% FBS 
 
 
 
4.2.2 Measurement of Cell Viability 
Cells were reverse transfected at 20nM on day 0 with a total of 100.5µL of 
volume in each well.  After 24 hours, 100µL of media was added for a total 
volume of 200.5µL.  144 hours later, 20 µL of 1:1 mixture of Cell Titer Blue (CTB) 
from Promega and Hank’s Buffered Salt Solution (HBSS) was added to each well 
and incubated for an optimized time interval between three and five hours before 
reading out the results using the EnVision Multilabel Plate Reader (PerkinElmer).  
This viability assay measures the metabolic activity of the living cells to convert 
resazurin to the fluorescent metabolite resorufin as an estimate of the number of 
viable cells.  Fluorescence is recorded at room temperature using an excitation 
filter at 570 nm and an emission filter at 590 nm. 
 
Hierarchical clustering of viability data was performed using TIGR Multiple Array 
Viewer.  Clusters were identified using hierarchical clustering based on average 
linkage and Euclidean distance. 
 
4.2.3 Estradiol Exposure 
LCC1 and LCC9 cells were cultured in the absence and presence of 1nM 
estradiol (Sigma).  Cells were seeded at 2,000 cells per well. Cells were reversed 
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transfected with siRNAs at 20nM in triplicate and incubated at 37°C and 5% CO 2.  
Viability was measured 144h post-transfection as described in 3.2.2.  Viability 
was calculated as a ratio of the median of negative control. 
 
4.2.4 Measurement of Caspase 3/7 Activity 
LCC1 and LCC9 cells were seeded at 6,250 cells per well. Cells were reverse 
transfected with siRNAs at 20nM in triplicate and incubated at 37°C and 5% CO 2 
for 120 hours.  After 120h, caspase 3/7 activity was measured using Apo-ONE as 
described by Promega.  Fluorescence was measured using the EnVision 
Multilabel Plate Reader from PerkinElmer. Caspase 3/7 activity for each gene 
knockdown was calculated by normalizing to median fluorescence values of non-
silencing controls on the plate.   
 
4.2.5 Measurement of Proliferation 
LCC1 cells were seeded at 2,000 cells per well. Cells were reversed transfected 
with siRNAs at 20nM in triplicate and incubated at 37°C and 5% CO 2 for 24h, 
48h, 72h, 96h, 120h or 144h.  Every 24h post transfection, proliferation was 
measured using the cell proliferation ELISA BrdU chemiluminescent kit (Roche).  
Luminescence was measured using the EnVision Multilabel Plate Reader 
(PerkinElmer). BrdU incorporation for each gene knockdown was calculated by 
normalizing to median luminescence values of non-silencing controls (NEG) on 
the plate.  
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4.2.6 Evaluation of Drug Response 
LCC1, LCC9 and MCF7 cells were seeded at densities leading to 80% 
confluence on day 7 in the appropriate medium in the absence of treatment.  
Cells were incubated at 37°C and 5% CO 2 for 7 days.  Twenty-four hours after 
cell seeding, cells were treated with Bortezomib with final well concentrations 
ranging from 2.5nM - 2.5µM. Viability was measured as described in 3.2.2.  
Viability was calculated as a percentage of the untreated cells.  
 
In addition, MCF7, LCC1 and LCC9 cells were also treated with the RNA pol II 
inhibitor, alpha-amanitin.  Each cell line was treated with alpha-amanitin in the 
range of 1nM – 10µM for 144 h. MTS assay were performed to measure the 
cytotoxicity.  Cytotoxicity was measures as a percentage of untreated cells. 
 
4.2.7 Network Analysis 
The list of genes in the EIPS genes subset was submitted into STRING to 
identify only experimentally verified protein-protein interactions.  Nodes in the 
ER-centered network were sorted using Cytoscape based on the number of 
protein-protein interactions for each node, degree centrality, to identify hubs.  
With no definitive standard for classifying hubs, a node was designated as a hub 
in the ER-centered network if it was in the top 5% of nodes with the highest 
degree centrality. 
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4.3 Results 
 
4.3.1 Changes in Viability in Breast Cancer Cell Lines 
We selected 25 genes from the LCC1/LCC9 viability group for more in depth 
analysis, estrogen independent pro-survival gene set (EIPS).  To determine 
whether their role in viability was specific in LCC1 and LCC9 versus MCF7 cells, 
or more generally reflected a requirement in estrogen-independent versus 
estrogen-dependent cell lines, we analyzed the consequences of depletion in five 
additional breast cancer cell lines: MDA-MB231 (triple negative, estrogen-
independent), T47D (ERα-positive, estrogen dependent, and 
tamoxifen/fulvestrant sensitive), T47Dco (ERα-positive, estrogen independent, 
and tamoxifen/fulvestrant resistant), BT-474 (ERα-positive, estrogen-dependent), 
and MCF10A (similar to normal mammary epithelial cells).  See Table 7 for a 
complete list of cell lines and AE/AI sensitivities.  This analysis indicated that the 
group of 5 estrogen-independent breast cancer cell lines MDA-MB231, LCC1, 
LCC9, T47Dco, and T47D clustered together in requiring EIPS genes for viability, 
in contrast to the estrogen-dependent cell lines MCF10A, MCF7, and BT474, in 
which the EIPS genes were dispensable (Figure 27).  
 
Table 7 Sensitivity of Breast Cancer Cell lines to Estrogen and Anti-Estrogens 
Cell Line Estrogen  Tamoxifen Fulvestrant 
MCF7 Dependent Sensitive Sensitive 
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Cell Line Estrogen  Tamoxifen Fulvestrant 
LCC1 Independent Sensitive Sensitive 
LCC9 Independent Cross-
resistant 
Resistant 
T47D Dependent Sensitive Sensitive 
T47Dco Independent Resistant Resistant 
BT474 Dependent   
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Figure 27 This heatmap represents the viability of breast cancer and normal like 
cell lines after knockdown of the EIPS genes at 144 hours post-transfection.  The 
color scale represents viability from zero to one, with the darkest blue indicating a 
viability of zero and white representing a viability of one.  Clusters were identified 
using hierarchical clustering based on average linkage and Euclidean distance. 
 
 
 
4.3.2 Effects of Estradiol 
While LCC1 and LCC9 are estrogen-independent for growth, they retain ER and 
other estrogen receptors, which may retain some biological activities.  Potentially, 
requirement for some or all of the genes in the EIPS set might be influenced by 
available estrogen. Culturing of the estrogen independent breast cancer cell lines 
LCC1 and LCC9 in 1nM estradiol resulted in no significant change in viability 
after individual knockdown of 25 genes associated with estrogen-independence.  
  
 
 
85
These results also demonstrate a clear difference in the viability of the estrogen 
independent cell lines and their parental, estrogen dependent MCF7 cell line in 
response to individual gene knockdown, as seen in a representative example of 
the proteasomal subunit PSMD1 (Figure 28).  The results of these studies using 
this 25-gene subset are shown in Appendix 2 
 
 
Figure 28 Exposure to estradiol does not change the effect of the knock of 
PSMD1, one of the genes in the EIPS gene set in estrogen independent cell lines 
LCC1 and LCC9. 
 
 
 
4.3.3 Apoptosis and Proliferation in LCC1 and LCC9 Cells 
Knockdown of the EIPS gene set might reduce cell viability by decreasing cell 
proliferation, increasing apoptosis, or both.  Genes required for apoptosis 
resistance would be of particular interest as potential targets in cancer therapy, in 
contrast to those that primarily induce cytostasis.  Caspase 7 activity levels were 
assessed as surrogates for apoptotic induction following depletion of each of the 
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25 genes in the set of interest. Knockdown of 15 and 16 of the genes in the EIPS 
subset induced at least two-fold increases in caspase 7 activity in LCC1 and 
LCC9, respectively, In general, the degree of apoptotic induction associated with 
each gene in the set was comparable in the two lines, with knockdown of the 
transcription factor CNOT1, the polymerase II subunits POLR2B and POLR2C, 
and the proteasome component PSMB4 having the most significant effect 
(Figure 29).  
 
 
 
Figure 29 Caspase 7 activity as relative fluorescent units 120h post transfection 
of siRNAs targeting the 25 genes in the EIPS subset.  Approximately half of the 
genes knocked down induce caspase 7 activity by at least two-fold in LCC1 and 
LCC9 cells. 
 
 
 
The individual knockdown of every gene in the EIPS gene set reduces 
proliferation in estrogen independent breast cancer LCC1 cells.  A reduction in 
proliferation was observed by 144h post transfection for each gene in the EIPS 
subset.  Reduced proliferation was observed in both the apoptosis inducing and 
non-apoptosis inducing groups within the EIPS subset (Figure 30).  
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Figure 30 Proliferation measured using BrdU assay.  This bar graph represents 
proliferation 144h post-transfection of the EIPS genes in LCC1 cells.  The 
individual knockdown of each member of the EIPS gene subset reduces cell 
proliferation.   
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4.3.4 Phenocopy RNAi Knockdowns of Proteasomal and RNA Polymerase 
Subunits 
Drugs targeting the proteasome and RNA polymerase II were tested in estrogen 
dependent and independent cell lines to observe changes in viability.  The EIPS 
subset contains genes encoding several RNA pol II subunits. The RNA pol II 
inhibitor, α-amanitin, was used to determine the effect of RNA pol II 
pharmacologic inhibition in MCF7, LCC1 and LCC9 cells. These cells were 
exposed to 1 nM - 10 µM of α-amanitin for 144 h. MTS assays were performed to 
measure cytotoxicity.  Compared to MCF7 cells, LCC1 and LCC9 cells showed 
higher sensitivity to α-amanitin (Fig 31d), consistent with the results from siRNA 
screening (Fig 31a-c).  
 
Similarly, these cells were more sensitive to the FDA approved proteasomal 
inhibitor bortezomib, which is indicated for the treatment of multiple myeloma and 
lymphomas[84, 85]. Bortezomib treatment recapitulates estrogen independent 
breast cancer cells viability response to reduced proteasome function. Three of 
the genes in the EIPS gene set encode proteasomal subunits and when 
knocked-down reduce viability by more than 75% in the estrogen independent 
breast cancer cell lines LCC1 and LCC9.  In contrast, knockdown of these genes 
in the parental, estrogen dependent cell line, MCF7, only reduces viability by 
about 25% (Fig 32a-c).  Bortezomib concentration-response curves in each of 
these cell lines demonstrate that LCC1 and LCC9 cell lines are more sensitive to 
bortezomib compared to the MCF7 cell line (Fig 32d).  
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Figure 31 siRNA knockdown and pharmacological inhibition of RNA polymerase 
II reduces survival in LCC1 and LCC9 cells more compared to the parental 
estrogen dependent, MCF7 cells. (a-c) Viability reported as percentage of 
untreated 144h after siRNA knockdown of RNA polymerase II subunits POLR2A, 
POLR2B and POLR2C. (d) α-amanitin treated MCF7, LCC1 and LCC9 cells for 
144 h. MTS assay were performed to measure the cytotoxicity. Results are from 
3 independent experiments. Data are shown as mean values ± S.D. α-amanitin. 
Yongwei Zhang performed this experiment. 
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Figure 32 The proteasome inhibitor bortezomib is more effective in reducing 
viability in estrogen independent breast cancer cell lines than in parental MCF7 
cells. (a-c) Viability of LCC1, LCC9 and MCF7 cells 144h post transfection of 
proteasomal subunit genes siPSMB4, siPSMC5 and siPSMD1.  (d) Viability as 
percentage of untreated for LCC1, LCC9 and MCF7 cells after 120h treatment 
with proteasomal inhibitor, bortezomib. 
 
 
 
4.3.5 In Silico Analysis of EIPS Gene Set 
To better understand the relationships among the EIPS gene set an in silico 
analysis was performed.  Based on experimentally verified protein-protein 
interactions in the STRING database, the EIPS gene subset does not form a 
network.  The few protein-protein interactions among the 25 genes in the EIPS 
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gene subset result from family members interacting with each other (Fig 33a).  
The genes in the EIPS gene subset are, however, connected to nodes with 
higher degree centrality within the ER-centered network (Fig 33b).  We identified 
hubs in the ER-centered network as the top 5% of the nodes with highest degree.  
There are 32 hubs in the ER-centered network and none of the genes in the 
essential gene subset function as hubs. 
 
Mapping the EIPS gene subset back to the resources that were used to create 
the ER-centered network showed that all but one of the genes are first or second 
neighbors of 5 seed genes used to generate the network (Fig 33c).  Three of the 
EIPS genes are first neighbors and the other 21 genes are second neighbors.  
EIF31 and PRPF6 are first neighbors of ESR1 and DDX54 is first neighbor of 
both ESR1 and ESR2.  None of the genes in the EIPS gene subset are derived 
from the ER-complex datasets included in the ER-centered network.  There is a 
modest increase in the representation of the overlap between the PPI and 
Estrogen Responsive Genes Data set in the EIPS gene subset (37%) compared 
to the ER-centered network (31%).  A 15% increase in representation of the 
nodes that are only from the PPI data is observed in the EIPS gene subset (41%) 
compared to ER-centered network (26%). 
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Figure 33 (a) Experimentally verified protein-protein interactions among the 
genes in the EIPS genes subset identified from protein-protein interaction 
database STRING[2].  (b) The EIPS gene subset (red nodes) and the first 
neighbors (white nodes) within the ER-centered network based on experimentally 
verified protein-protein interactions and sorted by degree centrality.  (c) 
Breakdown of the EIPS gene subset within the sub groups that were used to 
create the network.   
 
 
 
4.4 Discussion 
We took a selection of the 49 genes identified in Chapter 2 for further 
investigation.  This gene set, referred to as EIPS, represents the range of 
viability, 0 – 0.5, from which the 49 genes were originally selected as putative 
hits.  These genes are essential to the viability of estrogen independent LCC1 
and LCC9 cells.  We chose to expand the breast cancer lines studied to 
determine whether the EIPS genes were essential specifically in the MCF7 
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derived cell lines or if they were more broadly essential to other estrogen 
independent cell lines.  We found the latter to be true.  Through hierarchical 
clustering of the viability data from several other breast cancer cell lines, we 
found that the estrogen independent cell lines cluster together and were much 
more sensitive when EIPS genes were depleted compared to the estrogen 
dependent and normal like cell lines.  Given the essentiality of the EIPS gene set 
to several estrogen independent cell lines, a more in depth understanding of how 
the gene depletion effects cellular viability and signaling is important for 
developing new targeted therapies. 
 
Additional studies were conducted in LCC1 and LCC9 cells to characterize 
cellular responses to gene knockdown.  The viability studies with estrogen 
independent cell lines were carried out in the absence of estrogen since it is not 
required for cell proliferation or survival.  However, these cell lines still express 
the estrogen receptor and therefore, ligand dependent signaling may alter the 
viability after gene knockdown.  The addition of estradiol did not alter the effects 
of siRNA knockdown of the EIPS gene set in LCC1 and LCC9 cells.  We 
hypothesize that this may be translatable to women in the clinic with AI 
resistance. 
 
Anti-proliferative effects or cell death may cause reduced viability from gene 
depletion of the EIPS set.  Proliferation was measured by BrdU DNA 
incorporation and the knockdown of all EIPS genes caused at least a 70% 
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reduction in proliferation by 144h post-transfection.   Approximately half of the 
EIPS gene depletions cause caspase 7 activation, an indicator of apoptotic 
activity, in LCC1 and LCC9 cells.  Among those genes inducing apoptosis are 
three genes each making up the proteasome and RNA polymerase II.  
 
The proteasome is involved in cellular degradation of proteins to control protein 
expression within the cell and remove miss-folded proteins.  Bortezomib, a 
proteasome targeted drug approved for treatment of multiple myelomas and 
lymphomas [84, 85], has been shown to reduce survival in Fulvestrant resistant 
MCF7 cells when used in combination with Fulvestrant [77].  Bortezomib alone 
decreased survival in LCC1 and LCC9 cells more compared to MCF7 cells.  This 
supports the same observation of reduced viability using siRNAs targeting the 
proteasomal subunits.  Similarly, alpha-amanitin, a drug targeting RNA 
polymerase II, also replicated the enhanced reduction in viability in LCC1 and 
LCC9 cells compared to MCF7 cells as observed with siRNAs targeting RNA 
polymerase II.  While neither of these drugs are currently approved for the 
treatment of breast cancer, development of new drugs and eventually, clinical 
trials targeting the EIPS proteins is important to pursue for the future treatment of 
estrogen independent breast cancer.   
 
Network analysis of the EIPS gene set revealed that they do not directly interact 
with each other to form a network.  However, many of the EIPS proteins form a 
network once it is expanded to the first neighbors of the 25 proteins.  Within this 
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network based on degree centrality the EIPS proteins are not hubs and an 
expanded hub analysis within the ER-centered network shows the same result.   
 
An analysis of the representation of the EIPS proteins in the ER-centered 
network concluded that there is over representation of PPI from the first 
neighbors of the 5 seed genes and to a lesser degree the intersection between 
the PPI and estrogen responsive genes.  The identification of EIPS proteins 
supports the creation and screening of the ER-centered library to understand 
estrogen independence in breast cancer.  While the over representation for the 
PPI first neighbors suggests this bioinformatic dataset was the highest 
contributor as a percentage increase, over half of the hits identified came from 
the intersection among the PPI, pathways, and estrogen responsive genes.  
Including multiple bioinformatic data types was important in creating a focused 
network that could be reiteratively screen to identify genes essential to the 
survival of estrogen independent breast cancer.   
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Chapter 5: Discussion and Future Directions 
 
Estrogen independence and resistance to anti-estrogen drugs are responsible for 
the deaths of many women with breast cancer. Here we describe for the first time 
a systems biology-informed, network-targeted siRNA library screening approach 
to identify genes that mediate estrogen independence. Such genes may offer 
promise as molecular targets that can be attacked to prevent or delay the onset 
of estrogen-independent breast cancer. 
 
We show here that a core set of genes in the estrogen receptor network 
mediates estrogen independence, and that the knockdown of any of these genes 
is selectively toxic to estrogen-independent breast cancer cells.  Screening 
breast cancer cell lines with varying estrogen dependence using siRNA 
technology led us to identify the genes essential once estrogen independence 
has been acquired.  Additionally, reduced proliferation and in some cases 
increased apoptotic activity after gene knockdown further confirmed the 
significance of each gene for cell survival. This screen focused on understanding 
estrogen independence using an estrogen receptor focused library.  Using a 
focused library allowed us to hone in on the driving signaling network of estrogen 
receptor positive breast cancer and enrich for putative survival hits.    
 
Interestingly, these pro-survival genes, all of which were selected for screening 
using systems biology approaches designed to enrich the siRNA library for 
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potential hits, do not form a recognizable network, suggesting that each gene 
acts relatively independently to achieve its effects.  To explore the connectivity of 
the EIPS gene set we used the experimentally verified protein-protein 
interactions from STRING[2].  This observation is further supported by the 
degree centrality analysis of the first neighbor network of the EIPS gene set, 
which showed the EIPS genes are not hubs within its closest network.  
Additionally, a hub analysis of the entire ER-centered network did not result in 
the identification of any of the genes in the EIPS subset.  Since estrogen-
independence typically evolves following physiological or pharmacological 
estrogen deprivation, these results suggest that these selection pressures induce 
many discrete survival routes that cells may employ.  Ongoing phosphoproteomic 
studies are exploring the changes in protein and phosphorylation levels to 
understand cellular signaling patterns after gene depletion of the EIPS gene set.   
 
The translational applicability of these results is highlighted by the use of 
bortezomib to phenocopy the results of PSMC5 knockdown and α-amanitin to do 
the same for POLR2B knockdown, respectively. While bortezomib has limited 
utility in the management of advanced estrogen-independent breast cancer [86], 
newer proteasomal inhibitors with improved penetration into solid tumors may be 
more useful[87]. While no RNA Polymerase II inhibitors have advanced to clinical 
development, triptolide inhibits RNA Polymerase II function through its actions on 
ERCC3, and may merit evaluation for breast cancer therapy [88]. The remaining 
EIPS proteins are potential candidates for drug development in treatment of AI 
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resistance.  Moreover, we speculate that the optimal use of agents that address 
estrogen independence may be in combination with anti-estrogens to prevent, 
delay or shape the development of drug resistance.  
   
The results of these studies demonstrate the diversity and flexibility of survival 
mechanisms as breast cancer cells develop estrogen independence. 
Interestingly, many different genes contribute to survival in this setting, 
challenging previous conventions that estrogen independence and resistance to 
anti-estrogen drugs involve the gradual accumulation of resistance mechanisms. 
Current studies are addressing this possibility directly by examining survival 
networks as estrogen receptor positive breast cancer cells acquire estrogen 
independence in the course of estrogen deprivation.  
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Contributions 
• Identified a gene set, EIPS, essential for breast cancer cell survival after 
acquired estrogen independence by probing an estrogen receptor 
centered library using siRNA technology. 
• The knockdown of any of the EIPS genes is selectively toxic to estrogen-
independent breast cancer cells through reduced proliferation and/or 
increased apoptotic activity.   
• The EIPS gene set does not form a protein interaction network suggesting 
that antiestrogen and aromatase inhibitor resistant breast cancer cells 
employ several different routes of survival. 
• Phenocopy data using pharmacological inhibition targeting RNA 
polymerase II subunits and proteasomal subunits demonstrates the 
potential translational applicability of the EIPS as drug target candidates 
for the treatment of estrogen independent breast cancer. 
• As breast cancer cells acquire estrogen independence, they demonstrate 
flexible and diverse survival mechanisms.   
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Appendix 1: ER-Centered Network Gene List 
 
 
 
Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
21 ABCA3 X 
5243 ABCB1 X X 
196 AHR X 
11214 AKAP13 X X 
1109 AKR1C4 X X 
207 AKT1 X X 
208 AKT2 X X 
10000 AKT3 X X 
214 ALCAM X X 
238 ALK X X 
8125 ANP32A X 
302 ANXA2 X X 
162 AP1B1 X LCC1 LCC9  LCC1 
367 AR X X    
369 ARAF X X    
374 AREG X X X    
22899 ARHGEF15 X LCC1   LCC1 
405 ARNT X    
9915 ARNT2 X X    
84164 ASCC2 X LCC1   
9070 ASH2L X X    
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0
9
Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
440 ASNS X X    
445 ASS1 X X LCC1   LCC1 
1386 ATF2 X X  LCC9  LCC9 
467 ATF3 X X    
8312 AXIN1 X X LCC1   
8313 AXIN2 X    
558 AXL X X    
2683 B4GALT1 X X    
573 BAG1 X X LCC1 LCC9  LCC1 
85318 BAGE3 X    
578 BAK1 X X    
25805 BAMBI X X    
9031 BAZ1B X    
9564 BCAR1 X LCC1   LCC1 
10286 BCAS2 X LCC1 LCC9  
596 BCL2 X X X    
598 BCL2L1 X X    
10018 BCL2L11 X X    
604 BCL6 X X    
627 BDNF X X    
8553 BHLHB2 X X    
2647 BLOC1S1 X LCC1 LCC9  LCC1 X 
650 BMP2 X X X    
652 BMP4 X X  LCC9  LCC9 
653 BMP5 X X    
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1
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
654 BMP6 X X    
655 BMP7 X X LCC1 LCC9  
673 BRAF X X LCC1   LCC1 
672 BRCA1 X X    
685 BTC X X LCC1 LCC9  
689 BTF3 X X    
150135 C21orf129 X    
801 CALM1 X    
805 CALM2 X X  LCC9  LCC9 
808 CALM3 X    
10498 CARM1 X X LCC1   LCC1 
857 CAV1 X X    
6347 CCL2 X X    
6352 CCL5 X X LCC1 LCC9  
8900 CCNA1 X X LCC1   
891 CCNB1 X X    
595 CCND1 X X X LCC1   
902 CCNH X    
904 CCNT1 X    
905 CCNT2 X X    
10576 CCT2 X X LCC1 LCC9  
947 CD34 X X    
994 CDC25B X LCC1 LCC9  
984 CDC2L1 X X LCC1 LCC9  LCC1 X 
998 CDC42 X X    
  
 
 
1
1
1
Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
990 CDC6 X X    
8851 CDK5R1 X X    
1022 CDK7 X    
1051 CEBPB X X    
9620 CELSR1 X LCC1 LCC9  LCC1 
80152 CENPT X    
51287 CHCHD8 X X    
80205 CHD9 X    
1147 CHUK X X    
4435 CITED1 X LCC1 LCC9  
10370 CITED2 X X    
1182 CLCN3 X X    
1364 CLDN4 X LCC1 LCC9  LCC1 
7555 CNBP X X    
23019 CNOT1 X LCC1 LCC9  LCC1 X 
1268 CNR1 X X  LCC9  
25920 COBRA1 X LCC1 LCC9  LCC1 
10987 COPS5 X    
1358 CPA2 X X    
1385 CREB1 X X    
1387 CREBBP X X    
1390 CREM X X    
1394 CRHR1 X X    
285464 CRIPAK X LCC1 LCC9  
1401 CRP X X    
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
1436 CSF1R X X    
1454 CSNK1E X    
1460 CSNK2B X    
1487 CTBP1 X X X    
1488 CTBP2 X X    
1499 CTNNB1 X    
1500 CTNND1 X X    
1509 CTSD X X    
79004 CUEDC2 X LCC1   LCC1 
8451 CUL4A X X    
1727 CYB5R3 X LCC1   LCC1 
54205 CYCS X X    
1588 CYP19A1 X LCC1   
1555 CYP2B6 X X LCC1 LCC9  
3491 CYR61 X LCC1 LCC9  LCC1 X 
1649 DDIT3 X X    
780 DDR1 X X    
4921 DDR2 X X    
10521 DDX17 X    
1655 DDX5 X X LCC1 LCC9  
79039 DDX54 X 
LCC1 LCC9 
MCF7 LCC1 X 
10260 DENND4A X X    
1718 DHCR24 X X    
1740 DLG2 X X LCC1   
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
10294 DNAJA2 X X    
3337 DNAJB1 X X    
23317 DNAJC13 X    
1786 DNMT1 X    
30836 DNTTIP2 X LCC1   LCC1 
1826 DSCAM X X    
1843 DUSP1 X X    
1846 DUSP4 X X  LCC9  LCC9 
1848 DUSP6 X X    
1854 DUT X LCC1 LCC9  LCC1 
9166 EBAG9 X LCC1   
10682 EBP X    
1915 EEF1A1 X X    
2202 EFEMP1 X X    
1948 EFNB2 X X    
1950 EGF X X    
1956 EGFR X X    
112398 EGLN2 X X    
1959 EGR2 X X    
8668 EIF3I X LCC1 LCC9  LCC1 X 
2002 ELK1 X X LCC1 LCC9  
2026 ENO2 X X    
2033 EP300 X X LCC1   
2041 EPHA1 X X    
1969 EPHA2 X X LCC1   
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
2043 EPHA4 X X    
2047 EPHB1 X X    
2048 EPHB2 X X 
LCC1 LCC9 
MCF7 
2051 EPHB6 X X    
2056 EPO X X LCC1 LCC9  
2057 EPOR X X    
2064 ERBB2 X X X  LCC9  LCC9 
2065 ERBB3 X X  LCC9  LCC9 
2066 ERBB4 X X    
2071 ERCC3 X X   MCF7 
2079 ERH X X LCC1 LCC9  LCC1 
2099 ESR1 X X X LCC1   LCC1 
2100 ESR2 X X X    
2101 ESRRA X X    
2104 ESRRG X    
118460 EXOSC6 X    
26355 FAM162A X X    
2189 FANCG X LCC1 LCC9  LCC1 X 
2203 FBP1 X X LCC1 LCC9  LCC1 X 
2246 FGF1 X X    
2258 FGF13 X X    
2247 FGF2 X X    
26281 FGF20 X X    
2249 FGF4 X X    
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
2250 FGF5 X X LCC1 LCC9  
2252 FGF7 X X    
2253 FGF8 X X  LCC9  LCC9 
2260 FGFR1 X X    
2263 FGFR2 X X    
2261 FGFR3 X X    
2274 FHL2 X    
2277 FIGF X X    
2288 FKBP4 X X    
2314 FLII X    
2321 FLT1 X X    
2322 FLT3 X X    
2324 FLT4 X X X    
2353 FOS X X X    
2355 FOSL2 X X LCC1 LCC9  
2296 FOXC1 X X LCC1 LCC9  
2308 FOXO1 X    
2309 FOXO3 X    
4303 FOXO4 X    
2444 FRK X X  LCC9  
2539 G6PD X X LCC1 LCC9  LCC1 
1647 GADD45A X    
4616 GADD45B X LCC1   LCC1 
10912 GADD45G X LCC1   
2597 GAPDH X X    
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Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
2619 GAS1 X X    
9518 GDF15 X X    
8200 GDF5 X X    
2661 GDF9 X X LCC1   
2671 GFER X X  LCC9  LCC9 
2697 GJA1 X X    
2768 GNA12 X X  LCC9  LCC9 
10672 GNA13 X X    
2770 GNAI1 X    
2771 GNAI2 X X    
2773 GNAI3 X X    
2776 GNAQ X X    
2778 GNAS X X    
2782 GNB1 X X X    
26354 GNL3 X X LCC1   LCC1 
2796 GNRH1 X X    
2798 GNRHR X    
10082 GPC6 X X    
2885 GRB2 X X    
9687 GREB1 X    
2891 GRIA2 X X    
23426 GRIP1 X X    
2957 GTF2A1 X X  LCC9  LCC9 
2958 GTF2A2 X X    
2959 GTF2B X X LCC1 LCC9  
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Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
2960 GTF2E1 X X    
2961 GTF2E2 X X    
2962 GTF2F1 X X    
2963 GTF2F2 X X LCC1   
2965 GTF2H1 X X LCC1   
2966 GTF2H2 X X    
2967 GTF2H3 X X    
2968 GTF2H4 X X LCC1   
404672 GTF2H5 X X    
2969 GTF2I X X    
3015 H2AFZ X X    
1839 HBEGF X X LCC1 LCC9  
3065 HDAC1 X X    
83933 HDAC10 X X    
3066 HDAC2 X X    
8841 HDAC3 X X    
9759 HDAC4 X X    
10014 HDAC5 X X   MCF7 
10013 HDAC6 X X X    
51564 HDAC7 X X    
55869 HDAC8 X X    
9734 HDAC9 X X    
3068 HDGF X X  LCC9  LCC9 
63897 HEATR6 X    
3280 HES1 X X    
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
10614 HEXIM1 X    
126961 HIST2H3C X X    
3123 HLA-DRB1 X X    
3146 HMGB1 X X    
3148 HMGB2 X    
3161 HMMR X X    
3172 HNF4A X    
3233 HOXD4 X X    
3265 HRAS X X    
3320 HSP90AA1 X X X LCC1 LCC9  
3326 HSP90AB1 X X    
7184 HSP90B1 X X    
3308 HSPA4 X X LCC1   
3309 HSPA5 X X LCC1   
3312 HSPA8 X X X LCC1 LCC9  
26353 HSPB8 X X    
3329 HSPD1 X X    
3383 ICAM1 X X LCC1 LCC9  
9592 IER2 X X LCC1 LCC9  LCC1 X 
8870 IER3 X X    
7866 IFRD2 X X LCC1 LCC9  LCC1 
3479 IGF1 X X LCC1 LCC9  
3480 IGF1R X X X X    
3481 IGF2 X X X LCC1   
3487 IGFBP4 X    
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
3488 IGFBP5 X X LCC1 LCC9  
3551 IKBKB X X    
9641 IKBKE X X LCC1   
8517 IKBKG X X LCC1 LCC9  LCC1 
3558 IL2 X X    
3562 IL3 X X    
3569 IL6 X X X    
3578 IL9 X X    
3622 ING2 X X    
3625 INHBB X LCC1   LCC1 
3643 INSR X X LCC1   
3667 IRS1 X X LCC1 LCC9  LCC1 
3670 ISL1 X    
3675 ITGA3 X X    
3685 ITGAV X X LCC1   LCC1 
23421 ITGB3BP X LCC1   
5927 JARID1A X LCC1 LCC9  LCC1 
3725 JUN X X X    
3726 JUNB X X    
3727 JUND X LCC1   LCC1 
2648 KAT2A X X X    
8850 KAT2B X X LCC1   
10524 KAT5 X LCC1 LCC9  
3791 KDR X X X    
547 KIF1A X LCC1 LCC9  LCC1 X 
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
3815 KIT X X    
7071 KLF10 X X X LCC1   LCC1 
9622 KLK4 X    
3880 KRT19 X X LCC1   
3854 KRT6B X X    
3855 KRT7 X X    
3932 LCK X LCC1 LCC9  
3934 LCN2 X X LCC1 LCC9  
3939 LDHA X X    
7044 LEFTY2 X X LCC1   
3977 LIFR X X LCC1   LCC1 
29931 LOH3CR2A X    
51691 LSM8 X LCC1 LCC9  
1130 LYST X    
23499 MACF1 X LCC1   
4085 MAD2L1 X LCC1   LCC1 
4131 MAP1B X X    
5604 MAP2K1 X X LCC1   
5606 MAP2K3 X X LCC1 LCC9  LCC1 
6416 MAP2K4 X X LCC1   
5608 MAP2K6 X X    
4214 MAP3K1 X X    
4215 MAP3K3 X X LCC1   
4216 MAP3K4 X X LCC1   
4217 MAP3K5 X X    
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
1326 MAP3K8 X X   MCF7 
5594 MAPK1 X X    
5602 MAPK10 X X    
5600 MAPK11 X X LCC1 LCC9  
6300 MAPK12 X X LCC1 LCC9  LCC1 
5603 MAPK13 X X    
1432 MAPK14 X X    
5595 MAPK3 X X    
5599 MAPK8 X X    
5601 MAPK9 X X    
4193 MDM2 X LCC1  MCF7 LCC1 
4204 MECP2 X LCC1   
5469 MED1 X X X    
84246 MED10 X    
9968 MED12 X X    
9969 MED13 X X LCC1 LCC9  
10025 MED16 X    
9440 MED17 X X    
9477 MED20 X X    
9412 MED21 X X LCC1 LCC9  
9862 MED24 X X LCC1 LCC9  LCC1 
10001 MED6 X X LCC1   
9443 MED7 X X    
4205 MEF2A X X    
4208 MEF2C X X    
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Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
10461 MERTK X X LCC1   LCC1 
4233 MET X X    
2872 MKNK2 X    
8085 MLL2 X X    
64210 MMS19 X LCC1   
4331 MNAT1 X    
4350 MPG X    
4486 MST1R X X    
4488 MSX2 X X    
9112 MTA1 X X LCC1   LCC1 
23788 MTCH2 X    
9961 MVP X LCC1   
4084 MXD1 X X LCC1 LCC9  LCC1 
4602 MYB X X    
4609 MYC X X LCC1   LCC1 
4617 MYF5 X X LCC1 LCC9  
84148 MYST1 X X LCC1   LCC1 
4685 NCAM2 X    
8648 NCOA1 X X    
10499 NCOA2 X X    
8202 NCOA3 X X    
8031 NCOA4 X    
23054 NCOA6 X LCC1   
135112 NCOA7 X    
9611 NCOR1 X X LCC1   
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
9612 NCOR2 X X    
10397 NDRG1 X X    
4790 NFKB1 X X    
4792 NFKBIA X X    
4830 NME1 X X    
4846 NOS3 X X X LCC1   
190 NR0B1 X X    
8431 NR0B2 X X    
9971 NR1H4 X    
7181 NR2C1 X    
7182 NR2C2 X  LCC9  LCC9 
7025 NR2F1 X LCC1 LCC9  LCC1 X 
2063 NR2F6 X    
3164 NR4A1 X X LCC1   
8013 NR4A3 X X    
4893 NRAS X X LCC1   
4899 NRF1 X X    
3084 NRG1 X X    
8204 NRIP1 X X X    
64324 NSD1 X LCC1   
4908 NTF3 X X    
4909 NTF4 X X    
4914 NTRK1 X X    
4915 NTRK2 X X    
4916 NTRK3 X X X LCC1   LCC1 
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Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
11162 NUDT6 X X    
5020 OXT X    
5036 PA2G4 X X LCC1   LCC1 
5058 PAK1 X    
56924 PAK6 X LCC1   LCC1 
5142 PDE4B X X LCC1 LCC9  
80310 PDGFD X X    
5156 PDGFRA X X LCC1   
5159 PDGFRB X X    
5174 PDZK1 X X    
27043 PELP1 X X    
5241 PGR X X    
11331 PHB2 X X LCC1   
22822 PHLDA1 X X    
8554 PIAS1 X    
9063 PIAS2 X    
10401 PIAS3 X    
5294 PIK3CG X X    
5295 PIK3R1 X X LCC1   LCC1 
8503 PIK3R3 X    
9373 PLAA X X    
5325 PLAGL1 X    
5327 PLAT X X    
5328 PLAU X X    
10769 PLK2 X X    
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Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
5366 PMAIP1 X X    
10957 PNRC1 X LCC1 LCC9  LCC1 X 
55629 PNRC2 X    
84172 POLR1B X    
5430 POLR2A X X 
LCC1 LCC9 
MCF7 LCC1 X 
5431 POLR2B X X LCC1 LCC9  LCC1 X 
5432 POLR2C X X LCC1 LCC9  LCC1 X 
5451 POU2F1 X LCC1 LCC9  
5457 POU4F1 X    
5458 POU4F2 X    
8613 PPAP2B X X    
10891 PPARGC1A X X    
133522 PPARGC1B X LCC1   
5473 PPBP X X LCC1   
5506 PPP1R3A X    
7799 PRDM2 X    
5566 PRKACA X X    
5567 PRKACB X X    
5573 PRKAR1A X X    
5575 PRKAR1B X X LCC1 LCC9  LCC1 
5576 PRKAR2A X X LCC1   
5580 PRKCD X X LCC1 LCC9  LCC1 
5618 PRLR X X    
3276 PRMT1 X LCC1 LCC9  LCC1 
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NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
3275 PRMT2 X    
5629 PROX1 X    
24148 PRPF6 X LCC1 LCC9  LCC1 X 
5664 PSEN2 X X LCC1   LCC1 
5692 PSMB4 X X LCC1 LCC9  LCC1 X 
5698 PSMB9 X LCC1 LCC9  
29893 PSMC3IP X    
5705 PSMC5 X LCC1 LCC9  LCC1 X 
5707 PSMD1 X X LCC1 LCC9  LCC1 X 
5728 PTEN X    
10728 PTGES3 X    
5743 PTGS2 X X    
5754 PTK7 X X LCC1 LCC9  LCC1 X 
5757 PTMA X X LCC1 LCC9  LCC1 
5764 PTN X X    
5770 PTPN1 X    
26469 PTPN18 X X    
5771 PTPN2 X X    
5777 PTPN6 X    
5793 PTPRG X X    
10076 PTPRU X X    
10744 PTTG2 X X    
5894 RAF1 X X    
5901 RAN X X    
5914 RARA X X  LCC9  LCC9 
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NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
5925 RB1 X    
5928 RBBP4 X X LCC1   
5929 RBBP5 X X    
5931 RBBP7 X X    
5932 RBBP8 X X    
55147 RBM23 X    
9584 RBM39 X LCC1 LCC9  
23543 RBM9 X    
5970 RELA X LCC1   
5979 RET X X    
57109 REXO4 X LCC1 LCC9  LCC1 
5992 RFX4 X  LCC9  LCC9 
5997 RGS2 X X    
5998 RGS3 X    
9604 RNF14 X    
6047 RNF4 X    
6098 ROS1 X X LCC1 LCC9  
6138 RPL15 X X    
6187 RPS2 X X 
LCC1 LCC9 
MCF7 LCC1 X 
6195 RPS6KA1 X X    
6197 RPS6KA3 X    
6237 RRAS X X LCC1 LCC9  
22800 RRAS2 X X    
6256 RXRA X LCC1   LCC1 
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NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
6280 S100A9 X X    
1901 S1PR1 X X    
6294 SAFB X    
9667 SAFB2 X    
6304 SATB1 X X  LCC9  LCC9 
6307 SC4MOL X X    
6337 SCNN1A X X LCC1 LCC9  LCC1 X 
10512 SEMA3C X X LCC1   
5265 SERPINA1 X X LCC1   
5104 SERPINA5 X X    
866 SERPINA6 X X    
5054 SERPINE1 X X    
6418 SET X X    
10946 SF3A3 X X LCC1 LCC9  LCC1 X 
9814 SFI1 X    
6446 SGK1 X X    
6464 SHC1 X X X    
53358 SHC3 X X    
6472 SHMT2 X X    
25942 SIN3A X X LCC1 LCC9  LCC1 
23309 SIN3B X X    
6558 SLC12A2 X X    
10463 SLC30A9 X    
54020 SLC37A1 X    
8140 SLC7A5 X    
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symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
4087 SMAD2 X X LCC1   LCC1 
4088 SMAD3 X    
4089 SMAD4 X    
6595 SMARCA2 X    
6597 SMARCA4 X X    
6602 SMARCD1 X    
6605 SMARCE1 X    
10592 SMC2 X X    
9342 SNAP29 X    
338428 SNORD109A X LCC1 LCC9  
54861 SNRK X X    
6626 SNRPA X X    
8835 SOCS2 X X    
6647 SOD1 X    
6654 SOS1 X X X    
6655 SOS2 X X LCC1   LCC1 
6667 SP1 X X X LCC1   LCC1 
6670 SP3 X LCC1   LCC1 
6671 SP4 X X LCC1   LCC1 
23013 SPEN X X LCC1   
6693 SPN X X LCC1 LCC9  
10252 SPRY1 X X    
10253 SPRY2 X X    
10011 SRA1 X LCC1   
6714 SRC X X    
  
 
 
1
3
0
Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
6720 SREBF1 X    
6776 STAT5A X X    
8614 STC2 X  LCC9  LCC9 
6801 STRN X LCC1 LCC9  
10273 STUB1 X X    
6817 SULT1A1 X X    
6819 SULT1C2 X X LCC1 LCC9  
84447 SYVN1 X LCC1   
4070 TACSTD2 X    
10474 TADA3L X X    
6872 TAF1 X X LCC1   
6881 TAF10 X X    
6882 TAF11 X X LCC1 LCC9  
6883 TAF12 X X    
6884 TAF13 X X    
8148 TAF15 X X    
9015 TAF1A X X    
9014 TAF1B X X LCC1   
9013 TAF1C X X    
138474 TAF1L X X    
6873 TAF2 X X LCC1 LCC9  LCC1 X 
83860 TAF3 X X    
6874 TAF4 X X    
6875 TAF4B X X    
6877 TAF5 X X    
  
 
 
1
3
1
Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
27097 TAF5L X X LCC1 LCC9  
6878 TAF6 X X    
10629 TAF6L X X    
6879 TAF7 X X    
54457 TAF7L X X    
6880 TAF9 X X    
51616 TAF9B X X    
6890 TAP1 X    
6908 TBP X X LCC1 LCC9  
84897 TBRG1 X X    
6919 TCEA2 X X    
6942 TCF20 X X LCC1   LCC1 
6996 TDG X    
7009 TEGT X X    
7010 TEK X X    
7031 TFF1 X X LCC1 LCC9  LCC1 
7980 TFPI2 X    
7039 TGFA X X X    
7040 TGFB1 X X LCC1 LCC9  
8563 THOC5 X X    
7066 THPO X X    
7067 THRA X    
7068 THRB X    
7075 TIE1 X X    
10245 TIMM17B X X    
  
 
 
1
3
2
Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
7078 TIMP3 X X    
7097 TLR2 X X    
8764 TNFRSF14 X LCC1 LCC9  
7136 TNNI2 X    
10140 TOB1 X X LCC1 LCC9  LCC1 X 
8940 TOP3B X X LCC1   LCC1 
7157 TP53 X X    
7164 TPD52L1 X X    
8805 TRIM24 X    
5987 TRIM27 X X LCC1   
10155 TRIM28 X LCC1   LCC1 
286827 TRIM59 X    
9325 TRIP4 X    
8295 TRRAP X X X    
7249 TSC2 X    
81628 TSC22D4 X X LCC1 LCC9  
10376 TUBA1B X    
203068 TUBB X LCC1 LCC9  LCC1 
7301 TYRO3 X X 
LCC1 LCC9 
MCF7 
7329 UBE2I X LCC1   LCC1 
7337 UBE3A X X    
7391 USF1 X X    
7392 USF2 X X    
6843 VAMP1 X X LCC1   
  
 
 
1
3
3
Entrez 
Gene Id 
NCBI gene 
symbol Complex PPI Pathway 
Estrogen 
Responsive 
Genes Primary Hit Validated Hit 
EIPS 
Gene 
7424 VEGFC X X    
54554 WDR5B X X    
55062 WIPI1 X    
8839 WISP2 X X    
7494 XBP1 X    
10897 YIF1A X X LCC1 LCC9  
7533 YWHAH X    
7704 ZBTB16 X    
7709 ZBTB17 X LCC1 LCC9  
55146 ZDHHC4 X X    
6935 ZEB1 X X    
7538 ZFP36 X X    
7773 ZNF230 X X    
10308 ZNF267 X X    
57541 ZNF398 X    
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Appendix 2: Estradiol Exposure of Estrogen Independent Pro-Survival 
Genes in LCC1 and LCC9 Cells 
 
 
 
 
 
Estradiol exposure to estrogen independent LCC1 and LCC9 cell line does not 
change the effect of gene knockdown of components of the EIPS subset on cell 
viability.  LCC1 and LCC9 cells were grown with or without 1 nM estradiol to 
observe the changes, if any, in the presence of estradiol.  Viability was calculated 
as a ratio compared to the non-silencing siRNA at 144h post-transfection. 
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